Next Article in Journal
Potential of Tryptamine Derivatives as Multi-Target Directed Ligands for Alzheimer’s Disease: AChE, MAO-B, and COX-2 as Molecular Targets
Previous Article in Journal
Synthesis and PET Imaging Biodistribution Studies of Radiolabeled Iododiflunisal, a Transthyretin Tetramer Stabilizer, Candidate Drug for Alzheimer’s Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 29
Issue 2
10.3390/molecules29020489
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Structure-Antitumor Activity Relationships of Aza- and Diaza-Anthracene-2,9,10-Triones and Their Partially Saturated Derivatives

by
Carmen Avendaño
*,
Pilar López-Alvarado
,
José María Pérez
,
Miguel Ángel Alonso
,
Eva Pascual-Alfonso
,
Miriam Ruiz-Serrano
and
J. Carlos Menéndez
*
Unidad de Química Orgánica y Farmacéutica, Departamento de Química en Ciencias Farmacéuticas, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain
*
Authors to whom correspondence should be addressed.
Molecules 2024, 29(2), 489; https://doi.org/10.3390/molecules29020489
Submission received: 29 December 2023 / Revised: 15 January 2024 / Accepted: 16 January 2024 / Published: 18 January 2024
Browse Figures
Versions Notes

Abstract

:
The 1,8-Diazaanthracene-2,9,10-triones, their 5,8-dihydro derivatives, and 1,8-diazaanthracene-2,7,9,10-tetraones, structurally related to the diazaquinomycin family of natural products, were synthesized in a regioselective fashion employing Diels–Alder strategies. These libraries were studied for their cytotoxicity in a variety of human cancer cell lines in order to establish structure–activity relationships. From the results obtained, we conclude that some representatives of the 1,8-diazaanthracene-2,9,10-trione framework show potent and selective cytotoxicity against solid tumors. Similar findings were made for the related 1-azaanthracene-2,9,10-trione derivatives, structurally similar to the marcanine natural products, which showed improved activity over their natural counterparts. An enantioselective protocol based on the use of a SAMP-related chiral auxiliary derived was developed for the case of chiral 5-substituted 1,8-diazaanthracene-2,9,10-triones, and showed that their cytotoxicity was not enantiospecific.

Graphical Abstract

1. Introduction

Natural products containing a 9,10-anthracenedione substructure are well known and have been widely studied as dyes [1] and for their anticancer activity [2], among other properties. They include antitumour compounds such as the anthracyclines [3,4,5], the pluramycins [6,7,8] and some of the enediyne antibiotics [9,10]. On the other hand, their hetero analogues are less common. We have focused on the synthesis and study of analogues of less known structures such as 1-aza- and 1,8-diaza-9,10-anthracenediones [11,12].
The deoxyniboquinones [13,14] and the diazaquinomycins (DAQs) are the only natural products derived from the 1,8-diazaanthracene-2,7,9,10-trione framework, although some related natural products, like nybomycin, are known [15,16]. After its isolation from a Streptomyces strain, the Ōmura group found that diazaquinomycin A (DAQA) possessed antibacterial properties [17,18], which they subsequently proposed to be due to its ability to inhibit thimidylate synthase [19]. Both findings made DAQA an attractive lead compound in the field of cancer chemotherapy; although the natural product itself lacked useful antitumor activity because of its poor pharmacokinetic properties [20]. On the other hand, subsequent studies by Murphy that involved the screening of an actinomycete secondary metabolite library against an ovarian cancer cell line led to the identification of the diazaquinomycins E, F and G [21], and a similar study by the same group of a library of aquatic bacterial natural product fractions led to the discovery of diazoquinomycins H and J, and also a promising in vitro activity profile for some DAQs against a panel of drug-resistant Mycobacterium tuberculosis strains [22] (Figure 1, compounds 1). Interestingly, diazaquinomycin biosynthetic gene clusters have been sequenced from marine and freshwater actinomycetes [23].
The structurally related 1-azaanthracenones are another class of natural compounds with interesting anticancer activity. In 1999, Soonthornchareonnon et al. described the cytotoxic activity of marcanine A, isolated from the stem bark of Goniothalaus marcanii [24], and its derivatives [25] against several tumor cell lines (Figure 1, compounds 2). Subsequently, these compounds have also been found to exhibit antimalarial activity against Plasmodium falciparum [26,27]. Jacobs et al. evaluated the cytotoxic activity of a series of compounds with an azaanthracenedione structure, finding that the quinone scaffold and the lactam moiety are important for activity [28]. Their mechanism of action is not clear, although some marcanine derivatives have been found to induce apoptosis via caspase-3 activation [29].
To date, there are no conclusive data about structure–activity relationships for diazoquinomycin analogues. The preparation and study of a number of semisynthetic analogues of DAQA (compounds 3 and 4) led Ōmura to the conclusion that the bis-lactam structure of the natural product was an essential requisite for thimidylate synthase inhibition and antitumor activity [30]. However, when we investigated the antitumor activity of a small set of derivatives of the structure 5, we found that they exhibited good antitumor activities, particularly towards solid tumors [31], while the introduction of a fluorine atom at C-3 led to compounds with antileukemic activity [32]. In order to assist the establishment of structure–activity relationships within this class of compounds, we describe here a systematic study of the in vitro antitumor properties of a large series of derivatives of structure 5, their 5,8-dihydro derivatives 6, where one of the electron-withdrawing pyridine nitrogen atoms has been replaced by an electron-releasing enamine-like moiety, 1-azaanthraquinones derived from structure 7 related to the marcanines and more simplified structures such as quinolinedione derivatives 8 where the lactam scaffold that appears to be essential for cytotoxic activity is maintained (Figure 2).

2. Results and Discussion

2.1. Preparation of 1,8-Diazaanthracene-2,9,10-trione Derivatives

Compounds 5 and 6 were prepared using hetero Diels–Alder chemistry [33,34,35,36,37]. The starting materials were, on the one hand, the unsaturated dimethylhydrazones 9, obtained [38,39] from N,N-dimethylhydrazine and the corresponding aldehydes, which are commercially available with the exception of 2-methyl-2-hexenal, synthesized using a literature procedure [40] (Table 1). On the other hand, the quinones 8 acting as dienophiles were obtained from simple aromatic starting materials using literature methods based on the Knorr [41,42,43,44] and Meth–Cohn [45] quinoline syntheses, followed by an oxidative demethylation reaction (Table 2).
The course of the reaction between compounds 9 and 8 depended on their substituent distribution (Scheme 1); thus, combinations of hydrazones 9 and quinones 8 (R4, R5 ≠ H) gave 5,8-dihydro-1,8-diazaanthraquinones 6 as the sole cycloadducts, while other combinations gave the fully aromatic compounds 5 [33,46] with the exception of the reaction between azadiene 9b and quinone 8h, which, together with 5p, gave a significant amount of the corresponding dihydro derivative 6p that could not be isolated in pure form. In this particular case, the reaction crude was treated with manganese dioxide to force the dehydrogenation of 6p. As a secondary product of the reaction, compound 10 was obtained from the addition of dimethylamine to the starting quinones 8, followed by spontaneous air oxidation (Table 3, method A). These side products were formed in a higher yield when dimethylhydrazone derivatives of crotonaldehyde were used; in these cases, a method previously described by our group based on the use of a silica gel support [34] allowed us to considerably reduce the formation of 10 (Table 3, method B). Alternatively, some of the reactions were performed in the presence of a chloroformyl polystyrene resin in order to trap the liberated dimethylamine [35] (Table 3, method C).
The reaction between azadiene 9b and quinone 8f afforded compound 5n as the main reaction product, together with a small amount of a derivative oxidized at the C4 benzylic position (5ah) (Scheme 2).
The hetero Diels–Alder reactions performed were usually regioselective, according to the previous experience of our group in similar reactions [33,46], and afforded only the 1,8-diazanthracene-2,9,10-trione structure. The selectivity of the process towards the C6 end can be attributed to the combination of two electronic factors: the conjugation of the carbonyl at C-5 with the lactam nitrogen and the deficiency created at C8=O as a consequence of its conjugation with the C2=O group and the existence of an intramolecular hydrogen bond with N1-H [33]. In one case, as shown in Scheme 3, the reaction of 1-(4-tolyl)-1-H-2,5,8-quinolinetrione (8h) with azadiene 9b afforded significant amounts of the regioisomer 1,5-diaza adduct 11 (5p:11 = 2:1). In this case, the presence of an aryl group on N1 of the quinone may alter the first effect mentioned above because of the partial transfer of the nitrogen charge towards the aromatic ring; on the other hand, the presence of a substituent on N1 may affect the coplanarity of the system, hindering the conjugative effects described above and also leading to the loss of the N1-H bond.
The reaction of C4-substituted 1-dimethylamino-1-azadienes affords C5-substituted 5,8-dihydro-1,8-diazaanthracene-2,9,10-trione systems, which are chiral and contain a stereogenic center at C5. It was considered of interest to obtain one of the compounds of this series in enantiomerically pure or enriched form in order to evaluate the stereospecificity of the antitumor activity. To achieve asymmetric induction in the Diels–Alder reaction, it was decided to employ chiral auxiliaries attached to the azadiene structure, which were synthetized from chiral 1-aminopyrrolidine derivatives obtained from (S)-N-benzyl ethyl prolinate and (R)-N-benzyl ethyl prolinate using a route described in the literature [47]. The only chiral dimethylamino-1-azadiene previously studied as a Diels–Alder diene is an analogue of compound 12a, containing an additional methyl at C-2 and derived from the Enders SAMP chiral auxiliary, which gave cycloadducts with maleic anhydride and maleimide derivatives in 76–98% enantiomeric excess (ee) [48]. Therefore, the reaction of 12a with quinone 8c was employed for optimizing our process. After some unsuccessful initial attempts at room temperature, we found that the reaction between 12a and 8c in refluxing chloroform for 3.5 h gave the desired adduct 6ai although in moderate yield (40%) and enantioselectivity (40% ee). The more hindered diphenyl diene 12b also gave poor results, but its dimethyl analogue 12c afforded 6ai in 40% yield and 85% ee. Similarly, the reaction of quinone 8c with 12d, the enantiomer of 12c, under the same conditions gave 6aj in 30% yield and 83% ee. The configuration of the C5 stereocenter in these compounds was proposed according to the endo transition state shown in Scheme 4, according to a literature proposal for this type of azadienes [48]. The level of stereoselection achieved with azadienes 12c and 12d was considered enough for a comparison of the activities of enantiomeric derivatives of the structure 6.
In order to complete the library of compounds 5, the dehydrogenation of their dihydro derivatives 6 (Scheme 5) was examined by comparing two methods, namely treatment with manganese dioxide (method A), which afforded good to excellent yields under mild conditions and air oxidation at high temperature (method B), which was efficient but rather slow. In the case of compound 5r, air oxidation was carried out in the presence of NaOH at room temperature (method C) (Table 4).

2.2. Preparation of 1-Azaanthracene-2,9,10-trione Derivatives 7

The deaza analogues 7 of the previously obtained compounds were prepared using standard Diels–Alder chemistry from quinones 8 and dienes 13 using thermal reaction conditions in sealed tubes [49] (Scheme 6 and Table 5). Compound 7f is the natural product marcanine A [24].
In some cases, it was not possible to obtain the aromatic compound 7 in a single step, although the level of oxidation of the obtained cycloadducts could be controlled by modifying the reaction conditions. Thus, the reaction between quinone 8b and 2,3-dimethyl-1,3-butadiene in ethyl acetate at 100 °C led to the formation of the primary Diels–Alder adduct 14. The reaction in the same solvent under increased reaction temperature (120 °C) gave a mixture of the aromatic derivative 7g and 14, which by reaction with DDQ in benzene at reflux for 7 h finally afforded the target compound 7g as a single product in 56% overall yield (Scheme 7).
In order to study the activity of some 5,8-dihydro derivatives of the 1-azaanthracenetrione framework, we resorted to modulating the reaction conditions to prevent the full aromatization of the primary Diels–Alder adduct. Thus, compound 15 was obtained, together with the corresponding aromatic derivative 7d, as a minor product of the reaction of quinone 8b with piperylene (1,3-pentadiene) in chloroform at 100 °C in a sealed tube for 24 h. Additional 5,8-dihydro-1-azaanthracenetrione derivatives were obtained using the diene anthracene (compound 16) and cyclopentadiene. In the latter case, the target compound 18 was obtained together with the corresponding hydroquinone 17, but this mixture was transformed into 18 by a simple reflux in methanolic sodium hydroxide (Scheme 8).

2.3. Biological Studies

The in vitro cytotoxicity of compounds derived from the structures 5, 6, 7, and 8 was studied in the following cell lines: mouse lymphoma (P-388), human lung carcinoma (A-549), human colon carcinoma (HT-29), human breast carcinoma (MCF-7), and human melanoma (MEL-28). For comparison purposes, we also evaluated the activity of diazaquinomycin A and some related compounds derived from structure 1 in these cell lines to establish a structure–activity relationship as conclusive as possible and determine the pharmacophore group. The results are shown in Figure 3, Figure 4, Figure 5, Figure 6, Figure 7, Figure 8, Figure 9, Figure 10 and Figure 11 and Tables S1–S6 in the Supporting Information expressed as inhibitory concentration 50 values (IC50, µM).
We first assessed the activity of simplified structures derived from the quinoline-2,5,8(1H)-trione framework (starting quinones 8), with the results shown in Figure 3 and Table S1. These compounds generally showed relatively modest activities and selectivities towards the tumors assayed, although three of the compounds (8c, 8k and 8l) had IC50 values against the P-388 leukemia cell line at the micromolar level, with some selectivity with respect to solid tumors. Nevertheless, the comparison of these activities with those shown below for the Diels–Alder and Diels–Alder adducts reveals the need for the tricyclic system in order to achieve good anticancer activity.
The unsubstituted 1-azaanthracenetrione derivative 7a showed the best antitumor activity of this series, and also selectivity against the lung cancer cell line, with an IC50 in the ten nanomolar range. Interestingly, this activity was superior to that of the marcanine B, C, and G natural products [24,25]. The presence of substituents at C7 and C8 considerably decreases their activity, as shown by the data for compounds 7d–7g. It is also relevant to note that the primary Diels–Alder adduct showed a higher activity than its aromatic counterpart 7g (Figure 4 and Table S2). The dihydro derivatives of the 1-azaanthracenetrione framework (compounds 15–18) substituted at C5 and C8 also maintained the anticancer activity, although with low selectivity (Figure 4 and Table S3).
Regarding the activity of derivatives of structure 5 (Figure 5, Figure 6 and Figure 7 and Table S4), our observations lead to the following conclusions:
(a)
Aromatic substituents at N-1 lower both activity and selectivity against solid tumors, as shown by the comparison of the data for compounds 5d and 5p.
(b)
Aromatic substituents at C-3 do not improve the activity on solid tumor cell lines with respect to alkyl groups when directly attached to the anthraquinone ring (5q vs. 5l and 5w vs. 5r)
(c)
On the other hand, when an aromatic ring is attached to C3 via a methylidene spacer, not only is considerable antitumor activity observed, but also a notable selectivity towards certain solid tumors. Thus, compound 5m is ten times more active in lung carcinoma and melanoma than in colon carcinoma and ca. 50 times more active than on the P-388 lymphoma cells. This difference also exists but is not so marked in the derivatives, which only present alkyl substituents at C3 such as 5l.
(d)
The presence of simultaneous substituents at C3, C4, and C5, leading to a steric interaction between the C10=O groups with R4 and R4, increases the activity against P-388 compared to the same compounds when they only have substituents at C4 and C5 or C3 and C4 (5u vs. 5t).
(e)
An increase in the length of the R5 chain seems to be accompanied by a slight decrease in activity in lung cancer cells (compounds 5g, 5j, and 5k). Aromatic substituents, especially when bearing an electron-releasing group, also lead to decreased activity in these cells (compounds 5h and 5i).
(f)
The presence of alkyl substituents at R6 is generally favorable for activity on the human colorectal adenocarcinoma cell line, as shown by the comparison of the data for 5c and 5d–f.
(g)
Electron-withdrawing groups decrease the activity when they are in the C3 and C4 positions with respect to their alkyl counterparts, as shown by the comparison between the compounds (5y, 5z, and 5aa vs. 5ad and 5ah vs. 5d).
The 1,5-diazaanthracenetrione framework seems to provide less active compounds than its 1,8-diaza isomer when substituted at C-7, as shown by the comparison of the activity data of compounds 5p and 12 (Figure 6 and Figure 8 and Table S4).
For 5,8-dihydro derivatives 6 (Figure 9 and Figure 10 and Table S5), the following conclusions were obtained:
(a)
Generally speaking, the aromatic compounds 5 and their 5,8-dihydro counterparts 6 show similar activities, but some exceptions to this rule were observed, as summarized below.
(b)
The presence of aromatic derivatives at C-5 increases the activity and selectivity against colon cancer cells in the dihydro derivatives such as 6h and 6i compared to their aromatized counterparts 5h and 5i. For N-aryl substitution, dihydro derivatives seem less selective for solid tumors (5v vs. 6v).
(c)
On the other hand, for the case of alkyl substitution the selectivity trend is the opposite one, with the aromatic systems 5 showing a higher selectivity for solid tumors than the corresponding compounds 6 (5s vs. 6s, 5t vs. 6t, 5u vs. 6u). Even though a comparison cannot be established in these cases, the lack of selectivity found in compounds 6ae, 6af, and 6ag supports this conclusion.
(d)
A comparison of the activities of the enantio-enriched compounds 6ai and 6aj leads to the conclusion that the configuration of the stereogenic center at C-5 does not greatly influence the anti-tumor activity.
Diazaquinomycins have been synthesized using double Knorr reactions, a strategy developed by Kelly [50] and Sun [51], or hetero Diels–Alder chemistry followed by N-oxidation and rearrangement, as described by us [44]. Diazaquinomycin A (1a) thus prepared exhibited a lower activity and selectivity than their corresponding derivative with a monolactam system (5u) and its 5,8-dihydro derivative (6u). Furthermore, additional structures derived from the diazaquinomycin framework (compounds 1b–e) showed a higher activity than the natural product but still lacked selectivity in their cytotoxicity (Figure 11 and Table S6).
Due to the importance of the multidrug resistance phenomenon (MDR) in cancer therapy, we also examined the effect of the representative compound 6h on two cell lines showing multidrug resistance due to the overexpression of glycoprotein Pgp-170, namely the HTC-15 colon and the UO-21 kidney cancer lines. As shown in Figure 12, compound 6h showed good activity in both cases.
Regarding the cytotoxicity mechanism of the compounds described here, compound 6h gave negative results in the following potential anticancer targets: thymidylate synthase (the putative target of diazaquinomycin A [18,19]), dihydrofolate reductase, topoisomerases I and II, ADN polymerases and ARN polymerases. It also failed to block DNA, RNA, or protein synthesis. Moreover, no clear-cut connection can be established between the half-wave redox potential of the quinone moieties in our compounds [25] and their activities. Additional studies will be needed to gain insight into the mechanism of action of our compounds, and in this connection, studies on the ability of our compounds to block the cell cycle at a particular stage will perhaps be informative. Due to the facts that the formation of DNA-damaging anion-radicals often contributes to the anticancer activity of quinones [52,53] and that the deoxynyboquinones have been shown to generate reactive oxygen species via their activation by quinone reductase NQO1 [14], this possibility will also be explored.

3. Materials and Methods

3.1. General Information

All reagents and solvents were of commercial quality, purchased from Sigma-Aldrich (Madrid, Spain) and were used as received. Reactions were monitored by thin layer chromatography on aluminium plates coated with silica gel and fluorescent indicator. Separation by flash chromatography were performed on SDS 60 ACC, 230–400 mesh or Scharlau Ge 048 silica gel. Melting points were measured with Reichert 723 hot stage microscope (Vienna, Austria), or in open capillary tubes using a Büchi immersion instrument, and are uncorrected. Infrared spectra were recorded on a Perkin–Elmer Paragon 1000 spectrophotometer (Tres Cantos, Spain), with solid compounds compressed into KBr pellets and liquid compounds placed between two NaCl disks. NMR spectra data were obtained using Bruker spectrometers (Rivas-Vaciamadrid, Spain) maintained by the CAI de Resonancia Magnética, UCM, operating at 250 and 300 MHz for 1H NMR and, 63 and 75 MHz for 13C NMR; chemical shifts (δ) are given in parts per million and coupling constants (J) in Hertz. Elemental analyses were determined by the CAI de Microanálisis, Universidad Complutense, using a Leco CHNS-932 combustion microanalyzer (Tres Cantos, Spain). The enantiomeric excess of compounds 6ai and 6aj was assessed by 1H-NMR in the presence of 1.5 equivalents of (+) tris(3-heptafluoropropylhydroxymethylene) europium camphorate.

3.2. Preparation of Enantiomerically Pure 1-Azadienes—General Procedure

To a solution of crotonaldehyde in dry ethyl ether (5 mL) is added a catalytic amount of acetic acid (0.02 mL) and 1.00–3.10 mmol of suitable chiral auxiliary. The resulting solution is heated at reflux in a bath at 45 °C in the absence of moisture for 30 min. After checking by TLC that the reaction is complete, it is allowed to cool at room temperature and washed with saturated aqueous sodium bicarbonate solution (1 mL × 2). The organic phase is dried with anhydrous sodium sulfate and evaporated, obtaining the desirable products.

3.2.1. (S)-N-(-But-2-en-1-ylidene)-2-(methoxymethyl)pyrrolidin-1-amine (12a)

This is obtained from 67 mg (0.96 mmol) of crotonaldehyde and 250 mg (1.90 mmol) of (S)-1-amino-methoxymethylpyrrolidine (SAMP), using the general procedure. Yield, 165 mg (95%) of compound 12a.
1H NMR (CDCl3, 250 MHz) δ: 6.97 (d, 1H, J = 8.9 Hz, H-1′); 6.17 (ddd, 1H, J = 15.4, 8.9 and 1.6 Hz, H-2′); 5.74 (dq, 1H, J = 15.4 and 6.8 Hz, H-3′); 3.55 (m, 2H, CH2-OCH3); 3.42 (m, 1H, H-2); 3.36 (s, 3 H, OCH3); 2.83 (m, 2H, H-5); 1.95 (m, 4H, H-3.4); 1.77 (dd, 3H, J = 6.7 and 1.5 Hz, H-4′ ppm. 13C NMR (CDCl3, 63 MHz) δ: 138.76 (C-1′); 130.46 (C-2′); 129.38 (C-3′); 74.63 (CH2-O-CH3), 63.12 (C-2); 59.21 (OCH3): 49.55 (C-5); 26.67 (C-4); 22.22 (C-3); 18.22 (C-4′) ppm. These data were identical to those found in the literature [54].

3.2.2. (S)-N-(But-2-en-1-ylidene)-2-(methoxydiphenylmethyl)pyrrolidin-1-amine (12b)

This is obtained from 124 mg (1.70 mmol) of crotonaldehyde and 500 mg (1.70 mmol) of (2S)-2-(1,1-diphenyl-1-methoxy)methylpirrolydine [47], using the general procedure. Yield, 534 mg (90%) of compound 12b.
[Found: C, 79.34; H, 7.78; N, 8.25. C22H26N2O, requires C, 79.00; H, 7.84; N, 8.38]. 1H NMR (CDCl3, 250 MHz) δ: 7.40–7.20 (m, 10H, 2 C6H5), 6.86 (d, 1H, J = 8.9 Hz, H-1′), 6.11 (ddd, 1 H, J = 15.4, 8.9 and 1.6 Hz, H-2′), 5.67 (dq, 1H, J = 15.4 and 6.6 Hz, H-3′), 3.18 (t, 1H, J = 6.5 Hz, H-2), 3.03 (s, 3H, OCH3), 2.84 (m, 2H, H-5), 2.0–1.82 (m, 4H, H-3,4), 1.75 (dd, 3H, J = 6.7 and 1.6 Hz, H-4′) ppm. 13C NMR (CDCl3, 63 MHz) δ: 142.02 (C-1″), 141.22 (C-1′), 134.35 (C-2′), 131.09 (C-3′), 130.15 and 129.75 (C-3″, 5″), 128.58 and 125.93 (C-4”), 127.12 and 126.99 (C-2″, 6″), 85.96 (C-OCH3), 67.50 (C-2), 51.45 (OCH3), 50.57 (C-5), 26.34 (C-4), 23.31 (C-3), 18.28 (C-4′) ppm.

3.2.3. (S)-N-(2-(2-Methoxypropan-2-yl)pyrrolidin-1-yl)but-2-en-1-imine (12c)

Obtained from 221 mg of crotonaldehyde (3.10 mmol) and 500 mg (3.10 mmol) of (S)-2-(2-methoxypropan-2-yl)pyrrolidin-1-amine [47], using the general procedure. Yield, 541 mg (82%) of compound 12c.
[Found: C, 68.82; H, 10.66; N, 13.25. C12H22N2O, requires C, 68.53; H, 10.54; N, 13.32]. 1H NMR (CDCl3, 250 MHz) δ: 6.95 (d, 1H, J = 8.9 Hz, H-1′), 6.15 (ddd, 1H, J = 15.4, 8.9 and 1.6 Hz, H-2′), 5.70 (dq, 1H, J = 15.4 and 6.7 Hz, H-3′), 3.65 (m, 1H, H-2), 3.33 (s, 3H, OCH3), 2.85 (m, 2H, H-5), 1.90 (m, 4H, H-3,4), 1.75 (dd, 3H, J = 6.7 and 1.6 Hz, H-4′), 1.15–1.05 (2 s, 6H, 2CH3). 13C NMR (CDCl3, 63 MHz) δ: 136.18 (C-1′), 130.86 (C-2′), 129.80 (C-3′), 72.03 (C-O-CH3), 65.02 (C-2), 51.34 (OCH3), 49.68 (C-5), 24.93 (C-4), 23.93 (C-3), 22.97 and 21.07 (2 CH3); 18.5 (C-4′).

3.2.4. (R)-N-(2-(2-Methoxypropan-2-yl)pyrrolidin-1-yl)but-2-en-1-imine (12d)

Obtained from 79 mg (1.10 mmol) of crotonaldehyde and 180 mg (3.80 mmol) of (R)-2-(2-methoxypropan-2-yl)pyrrolidine-1-amine [47], using the general procedure. Yield, 140 mg (58%) of compound 12d, whose spectroscopic data are identical to those found for its enantiomer 12c. [Found: C, 68.88; H, 10.47; N, 13.46. C12H22N2O, requires C, 68.53; H, 10.54; N, 13.32].

3.3. Hetero Diels–Alder Reactions between Dimethylhydrazones 9 and Quinones 8—General Procedure

Method A: To a solution of quinones 8 (0.05 to 0.55 mmol) in chloroform or dry THF (5–20 mL) was added the suitable azadiene 9 (1.05 to 2 equiv.). The solution was stirred at room temperature (5 min–1 h), and the solvent was evaporated. The residue was chromatographed on silica gel eluting with a gradient from neat dichloromethane or ethyl ether to neat ethyl acetate to yield compounds 5 or 6 in the yields shown in Table 2.
Method B: To silica gel-supported suitable quinone 8 (0.06–0.55 mmol), the suitable dimethylhydrazone 9 was rapidly added (2 eq). The column was then eluted with a gradient from dichloromethane or ethyl ether to ethyl acetate, affording compounds 5 or 6 in the yields shown in Table 2.
Method C: A suspension of carboxy polystyrene resin, prepared from 2% cross-linked Merrifield resin (2–2.5 meq Cl/g, 200–400 mesh) using a literature method [55] (5.0 g) in dry toluene (20 mL) was stirred at room temperature under an argon atmosphere for 30 min. Thionyl chloride (20 mL) was added, and the suspension was refluxed for 24 h with vigorous stirring and then cooled. The chloroformyl polystyrene resin thus obtained was filtered and washed with toluene (2 × 25 mL) and ethyl ether (2 × 25 mL). If stored at −18 °C under argon, it could be used for 2–3 months without a significant loss of activity.
To a stirred suspension of the suitable 2,5,8(1H)-quinolinetrione 8 (0.25 mmol) and the chloroformyl polystyrene resin (1.25 g, 5 eq) in chloroform (30 mL) was added the suitable dimethylhydrazone 9 (0.60 mmol). The suspension was stirred at room temperature for 5 min and filtered. The filtrate was evaporated and then residue was chromatographed on silica gel, affording compounds 5 or 6 in the yields shown in Table 2.
Characterization data for new compounds follow. Exchangeable spectral assignments are marked with asterisks.

3.3.1. 6-Butyl-4-methyl-1H-1,8-diazaanthracene-2,9,10-trione (5f)

[Found: C, 68.58; H, 5.23; N, 9.21. C17H16N2O3 requires C, 68.91; H, 5.44; N, 9.45]; Mp, 190–193 °C. νmax (KBr): 3431 (NH), 1673 and 1645 (C=O) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 9.79 (br s, 1H, NH), 8.84 (s, 1H, C7-H), 8.37 (s, 1H, C5-H), 6.69 (s, 1H, C3-H), 2.81 (t, 2H, J = 7.7 Hz, C6-CH2), 2,68 (s, 3H, C4-CH3), 1.71–1.62 (m, 2H, C6-CH2-CH2), 1.43–1.34 (m, 2H, C6-(CH2)2-CH2), 0.94 (t, 3H, J = 7.1 Hz, C6-(CH2)3-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 181.04 (C-9), 176.51 (C-10), 160.28 (C-2), 155.23 (C-7), 151,86 (C-4), 145.43 (C-8a), 144.08 (C-6), 140.33 (C-9a), 134.50 (C-5), 130.52 (C-10a), 128.13 (C-3), 115.59 (C-4a), 33.26* (C6-CH2), 32.77* (C6-CH2-CH2), 22.79 (C4-CH3), 22.34 (C6-(CH2)2-CH2), 13.89 (C6-(CH2)3-CH3) ppm.

3.3.2. 5,8-Dihydro-4,6-dimethyl-5-propyl-1H-1,8-diazaanthracene-2,9,10-trione (6k)

Method A. From 81 mg of 9i (0.50 mmol) and 100 mg (0.50 mmol) of 8b. Reaction time 10 min, affording 51 mg (32%) of 6k and 49 mg (40%) of the corresponding quinone 10. [Found: C, 68.09; H, 6.16; N, 9.15. C17H18N2O3, requires C, 68.44; H, 6.08; N, 9.39]. Mp, 235–238 °C. νmax (KBr) 3420 (NH), 1654 (C=O) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 6.85 (d, 1H, J = 1.2 Hz, C3-H), 6.70 (br s, 1H, N8-H), 6.11 (d, 1H, J = 1.2 Hz, C7-H), 3.57 (t, 1H, J = 4.7 Hz, C5-H), 2.56 (d, 3H, J = 1.2, C4-CH3), 1.71 (d, 3H, J = 1.2 Hz, C6-CH3), 1.46 (m, 2H, C5-CH2), 1.17 (m, 2H, C5-CH2-CH2-), 0.8 (t, 3H, J = 7.9, C5-CH2-CH2-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 183.24 (C-9), 176.06 (C-10), 161.67 (C-2), 152.34 (C-4), 137.11 (C-9a); 136.70 (C-8a); 127.70 (C-3), 119.47 (C-7), 116.13 (C6), 115.24 (C-4a), 112.04 (C-10a), 35.85 (C5-CH2-CH2-CH3), 35.55 (C-5), 22.75 (C4-CH3), 18.95 (C5-CH2-CH2-CH3), 18.69 (C6-CH3), 14.43 (C5-CH2-CH2-CH3) ppm.

3.3.3. 3,4,6-Trimethyl-1H-1,8-diazaanthracene-2,9,10-trione (5l)

Method A. From 15 mg (0.07 mmol) of 8d and 10 mg (0.09 mmol) of 9b, affording 16 mg (76%) of 5l and 2 mg (11%) of the corresponding quinone 10. [Found: C, 66.86; H, 4.25; N, 10.45. C15H12N2O3 requires C, 67.16; H, 4.51; N, 10.44]; Mp, >300 °C. νmax (KBr): 3428 (NH), 1628 (C=O) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 9.71 (br s, 1H, NH), 8.84 (d, 1H, J = 1.6 Hz C7-H), 8.30 (d, 1H, J = 1.6 Hz, C5-H), 2.67 (d, 3H, J = 0.6 Hz, C4-CH3), 2.55 (s, 3H, C6-CH3), 2.26 (d, 3H, J = 0.6 Hz, C3-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 182.95 (C-9), 178.31 (C-10), 162.92 (C-2), 155.69 (C-7), 148,31 (C-4), 146.07 (C-8a), 145.58 (C-6), 141.33 (C-9a), 140.42 (C-3), 128.23 (C-10a), 116.65 (C-4a), 19.88 (C6-CH3), 19.26 (C4-CH3), 13.74 (C3-CH3) ppm. C-5 was not observed.

3.3.4. 3-Benzyl-4,6-dimethyl-1H-1,8-diazaanthracene-2,9,10-trione (5m)

Method B. From 18 mg (0.07 mmol) of 8e and 15 mg (0.12 mmol) of 9b to get 15 mg (68%) of 5m. [Found: C, 73.09; H, 4.48; N, 7.95. C21H16N2O3 requires C, 73.24; H, 4.68; N, 8.13]. Mp, 260–262 °C. νmax (KBr): 3421 (NH), 1641 (C=O) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 9.72 (br s, 1H, NH), 8.84 (s, 1H, C7-H), 8.29 (s, 1H, C5-H), 7.24 (br s, 5H, Ph-H), 4.14 (s, 2H, C3-CH2), 2.70 (s, 3H, C4-CH3), 2.55 (s, 3H, C6-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 181.26 (C-9), 176.33 (C-10), 160.59 (C-2), 155.28 (C-7), 147.63 (C-4), 143.63 (C-8a), 140.46 (C-6), 138.76 (C-1′), 138.33 (C-9a), 138.18 (C-3*), 135.22 (C-5), 130.89 (C-10a), 128.59 (C-2′, C-6′), 128.34 (C-3′, C-5′), 126.41 (C-4′) 116.05 (C-4a), 32.23 (C3-CH2), 19.21 (C6-CH3), 18.45 (C4-CH3) ppm.

3.3.5. 4-Ethyl-6-methyl-1H-1,8-diazaanthracene-2,9,10-trione (5n)

Method A. From 50 mg (0.25 mmol) of 8f and 33 mg (0.30 mmol) of 9b to obtain 46 mg (70%) of 5m, 6 mg (9%) of the corresponding quinone 10 and 5 mg (11%) of 5ah. [Found: C, 66.86; H, 4.29; N, 10.03. C15H12N2O3 requires: C, 67.16; H, 4.51; N, 10.44]. Mp, 301–303 °C. νmax (KBr): 3460 (NH), 1640 (C=O) cm−1. 1HNMR (CDCl3, 250 MHz) δ: 9.71 (br s, 1H, NH), 8.87 (d, 1H, J = 1.7 Hz, C7-H), 8.33 (d, 1H, J = 1.7 Hz, C5-H), 6.75 (s, 1H, C3-H), 3.15 (q, 2H, J = 7.3 Hz, C4-CH2-CH3), 2.58 (s, 3H, C6-CH3), 1.28 (t, 3H, J = 7.3 Hz, C4-CH2-CH3) ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 181.31 (C-9), 177.39 (C-10), 162.15 (C-2), 156.31 (C-4), 154.94 (C-7), 144.81 (C-8a), 143.75 (C-6), 139.66 (C-9a), 135.60 (C-5), 130.35 (C-10a), 125.64 (C-3), 114.71 (C-4a), 26.53 (CH2- CH3), 16.89 (C6-CH3), 12.40 (CH2-CH3) ppm.

3.3.6. 4-Acetyl-6-methyl-1H-1,8-diazaanthracene-2,9,10-trione (5ah)

Isolated as a side product of the preparation of 5n. [Found: C, 63.94; H, 3.46; N, 9.42. C15H10N2O4 requires: C, 63.83; H, 3.57; N, 9.93]. Mp >300 °C. νmax (KBr): 3570 (NH), 1715 (CO-CH3), 1650 (C=O, p-quinone) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 9.83 (br s, 1H, NH), 8.92 (br s, 1H, C7-H), 8.33 (br s, 1H, C5-H), 6.66 (s, 1H, C3-H), 2,59 (s, 3H, C6-CH3), 2.57 (s, 3H, C4-CO-CH3) ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 200.58 (CO-CH3), 180.03 (C-9), 176.56 (C-10), 162.49 (C-2), 155.33 (C-7), 152.16 (C-4), 145.40 (C-8a), 143.47 (C-6), 139.70 (C-9a), 134.90 (C-5), 129.05 (C-10a), 122.31 (C-3), 113.47 (C-4a), 30.06 (CO-CH3), 18.21 (C6-CH3) ppm.

3.3.7. 6-Methyl-4-(2-phenylethyl)-1H-1,8-diazaanthracene-2,9,10-trione (5o)

Method A: from 20 mg (0.07 mmol) of 8g and 9 mg (0.08 mmol) of 9b to get 49% of 5o and 15% of the corresponding quinone 10. Method B: From 40 mg (0.14 mmol) of 8g and 32 mg (0.29 mmol) of 9b to yield 82% of 5o. [Found: C, 72.82; H, 4.73; N, 8.22. C21H16N2O3 requires: C, 73.24; H, 4.68; N, 8.13]. Mp, 262–264 °C. νmax (KBr): 3416 (NH), 1662 (C=O) cm−1. 1HNMR (CDCl3, 250 MHz) δ: 9.75 (br s, 1H, NH), 8.90 (s, 1H, C7-H), 8.39 (s, 1H, C5-H), 7.32 (br s, 5H, Ph-H), 6.67 (s, 1H, C3-H), 3.40 (t deform, 2H, J = 7.6 and 8.1 Hz, C4-CH2), 2.92 (dd, 2H, J = 7.2 and 8.6 Hz, Ph-CH2), 2.60 (s, 3H, C6-CH3) ppm. 13C NMR (d6-DMSO, 63 MHz) δ: 181.29 (C-9), 176.59 (C-10), 160.94 (C-2), 154.65 (C-4), 153.67 (C-7), 144.23 (C-8a), 142.98 (C-6), 141.10 (C-1′), 139.26 (C-9a), 134.58 (C-5), 130.21 (C-10a), 128.48 (C2′, C6′), 128.29 (C3′, C5′), 128.20 (C-4′), 126.00 (C-3), 114.48 (C-4a), 36.45 (C4-CH2), 35.56 (Ph-CH2), 18.51 (C6-CH3) ppm.

3.3.8. 6-Methyl-1-(4-tolyl)-1,8-diazaanthracene-2,9,10-trione (5p)

After carrying out the Diels Alder reaction on 19 mg (0.07 mmol) of 8h and 16 mg (0.13 mmol) of 9b according to method B, the reaction crude was dissolved in 10 mL of dichloromethane and 62 mg (0.72 mmol) of 85% activated manganese oxide was added. The solution was stirred at room temperature for 24 h and filtered through a layer of celite which was washed twice with 30 mL chloroform. The combined organic phases were dried over anhydrous sodium sulphate, evaporated and purified by silica gel column chromatography eluting with a gradient from dichloromethane to ethyl acetate, yielding 12 mg (52%) of 5p, 6 mg (26%) of 11 and 2 mg (9%) of the corresponding quinone 10.
[Found: C, 72.58; H, 3.96; N, 8.12. C20H14N2O3 requires: C, 72.72; H, 4.27; N, 8.48]. Mp, >300 °C. νmax (KBr): 1684 (CO, p-quinone), 1665 (HN-CO) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 8.86 (d, 1H, J = 1.8 Hz, C7-H), 8.37 (d, 1H, J = 9.7 Hz, C4-H), 8.04 (d, 1H, J = 1.7 Hz, C5-H), 7.33 (d, 2H, J = 8.1 Hz, C3′,5′-H), 7.05 (d, 2H, J = 8.3 Hz, C2′,6′-H), 7.01 (d, 1H, J = 9.7 Hz, C3-H), 2.46 (s, 6H, C4′-CH3 and C6-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 179.06 (C-9), 177.88 (C-10), 162.30 (C-2), 155.91 (C-7), 144.34 (C-8a), 140.58 (C-6), 138.90* (C-9a), 138.74* (C-1′), 135.86 (C-4′), 135.72* (C-5), 135.00* (C-4), 130.10 (C-3′, C5′), 129.23 (C-10a), 127.03 (C-3), 126.64 (C-2′, C-6′), 119.33 (C-4a), 21.34 (C4′-CH3), 18.78 (C6-CH3) ppm.

3.3.9. 7-Methyl-1-(4-tolyl)-1,5-diazaanthracene-2,9,10-trione (11)

[Found: C, 72.63; H, 4.02; N, 8.57. C20H14N2O3 requires C, 72.72; H, 4.27; N, 8.48]. Mp, 300–302 °C. νmax (KBr): 1694 (CO, p-quinone), 1657 (HN-CO) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 8.76 (br s, 1H, C6-H), 8.27 (br s, 1H, C8-H), 8.26 (d, 1H, J = 9.6 Hz, C4-H), 7.29 (d, 2H, J = 8.1 Hz, C3′,5′-H), 7.04 (d, 2H, J = 8.6 Hz, C2′,6′-H), 7.00 (d, 1H, J = 9.8 Hz, C3-H), 2.51 (s, 3H, C7-CH3), 2.41 (s, 3H, C4′-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 180.17 (C-9), 176.31 (C-10), 162.38 (C-2), 155.60 (C-6), 145.80 (C-10a), 141.90 (C-7), 139.29 (C-9a), 138.67 (C-1′), 135.60 (C-4′), 135.16 (C-8), 134.04 (C-4), 130.09 (C-3′, C5′), 127.48 (C-8a), 126.82 (C-3), 126.55 (C-2′, C6′), 118.30 (C-4a), 21.42 (C4′-CH3), 19.07 (C7-CH3) ppm.

3.3.10. 6-Methyl-3-(p-tolyl)-1,8-diazaanthracene-2,9,10-trione (5q)

Method B: using 14 mg (0.05 mmol) of 8i and 12 mg (0.10 mmol) of 9b to afford 16 mg (94% of 5q. [Found: C, 72.63; H, 3.90; N, 8.69. C20H14N2O3 requires C, 72.72; H, 4.27; N, 8.48]. Mp, 298–300 °C. νmax (KBr): 3421 (NH), 1684 (CO, quinone), 1654 (HN-CO) cm−1; 1H NMR (CDCl3, 250 MHz) δ: 9.70 (s, 1H, NH), 8.88 (d, 1H, J = 1.7 Hz, C7-H), 8.35 (d, 1H, J = 1.7 Hz, C5-H), 8.23 (s, 1H, C4-H), 7.27 (d, 2H, J = 8.3 Hz, C2′,6′-H), 7.22 (d, 2H, J = 8.2 Hz, C3′,5′-H), 2.57 (s, 3H, C4′-CH3), 2.39 (s, 3H, C6-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 179.75 (C-9), 175.84 (C-10), 160.32 (C-2), 155.43 (C-7), 144.94 (C-8a), 140.18 (C-6), 139.99 (C-9a), 139.28 (C-3), 137.41 (C-4′), 134.95 (C-5), 131.77 (C-4), 131.48 (C-1′), 129.48 (C-10a), 129.25 (C-3′, C5′), 128.58 (C-2′, C6′), 116.52 (C-4a), 21.39 (C4′-CH3), 19.16 (C6-CH3) ppm.

3.3.11. 5,8-Dihydro-3,4,5-trimethyl-1H-1,8-diazaanthracene-2,9,10-trione (6r)

Method A: from 72 mg (0.36 mmol of 8d and 44 mg (0.39 mmol) of 9e to afford 30 mg (32%) of 6r and 37 mg (42%) of the corresponding quinone 10. Method B: from 45 mg (0.22 mmol of 8d and 50 mg (0.44 mmol of 9e to afford 42 mg (70%) of 6r and 3 mg (6%) of the corresponding quinone 10. [Found: C, 62.23; H, 5.18; N, 10.27. C15H14N2O3 requires C, 66.66; H, 5.22; N, 10.36]. Mp > 300 °C. νmax (KBr): 3426, 3285 (NH), 1648, 1630 (C=O) cm−1; 1H NMR (d5-pyridine, 250 MHz) δ: 9.99 (br s, 1H, NH), 6.63 (dd, 1H, J = 7.6 and 4.5 Hz, C7-H), 5.14 (t, 1H, J = 6.1 Hz, C6-H), 4.09 (m, 1H, C5-H), 2.80 (s, 3H, C4-CH3), 2.47 (s, 3H, C3-CH3), 1.49 (d, 3H, J = 6.5 Hz, C5-CH3) ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 184.28 (C-9), 177.11 (C-10), 161.90 (C-2), 145.39 (C-4), 138.18 (C-8a), 134.47 (C-9a), 124.07 (C-7), 115.04 (C-4a), 114.26 (C-10a), 107.88 (C-6), 26.22 (C-5), 24.63 (C5-CH3), 17.59 (C4-CH3), 12.92 (C3-CH3) ppm. The C3 signal was overlapped with others.

3.3.12. 5,8-Dihydro-4-ethyl-5-methyl-1H-1,8-diazaanthracene-2,9,10-trione (6s)

Method A: from 90 mg (0.44 mmol of 8f and 55 mg (0.49 mmol) of 9e to afford 34 mg (29%) of 6s and 64 mg (59%) of the corresponding quinone 10. Method B: from 60 mg (0.29 mmol of 8f and 66 mg (0.59 mmol of 9e to afford 66 mg (84%) of 6s. [Found: C, 66.37; H, 5.24; N, 9.97. C15H14N2O3 requires C, 66.65; H, 5.22; N, 10.36]. Mp, > 295 °C. νmax (KBr): 3580 (NH), 1655, 1645 (C=O) cm−1; 1H NMR (d5-pyridine, 250 MHz) δ: 10.12 (br s, 1H, NH), 6.98 (s, 1H, C3-H), 6.65 (dd, 1H, J = 7.6 and 4.5 Hz, C7-H), 5.13 (dd, 1H, J = 7.5 and 4.8 Hz, C6-H), 4.09 (qd, 1H, J = 6.5 and 6.4 Hz C5-H), 3.29 (m, 2H, C4-CH2-CH3), 1.46 (d, 3H, J = 6.5 Hz, C4-CH2-CH3), 1.34 (t, 3H, J = 7.3 Hz, C4-CH2-CH3 ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 183.65 (C-9), 177.32 (C-10), 162.43 (C-2), 156.42 (C-4), 138.22 (C-8a), 135.74 (C-9a), 125.38 (C-3), 124.24 (C-7), 114.43 (C-4a), 114.35 (C-10a), 108.00 (C-6), 27.95 (CH2-CH3), 26.98 (C-5), 24.73 (C5-CH3), 14.30 (CH2-CH3) ppm.

3.3.13. 5,8-Dihydro-5-methyl-4-propyl-1H-1,8-diazaanthracene-2,9,10-trione (6t)

Method A: from 120 mg (0.55 mmol of 8j and 65 mg (0.58 mmol) of 9e to afford 50 mg (32%) of 6t and 72 mg (50%) of the corresponding quinone 10. Method B: from 25 mg (0.09) mmol of 8j and 20 mg (0.18 mmol of 9e to afford 30 mg (92%) of 6t. [Found: C, 67.80; H, 5.56; N, 10.06. C16H16N2O3 requires C, 67.59; H, 5.67; N, 9.85]. Mp, 234–236 °C. νmax (KBr): 3401 (NH), 1660, 1625 (C=O) cm−1; 1H NMR (d5-pyridine, 250 MHz) δ: 10.10 (br s, 1H, NH), 6.98 (s, 1H, C3-H), 6.64 (dd, 1H, J = 7.6 and 4.5 Hz, C7-H), 5.13 (m, 1H, C6-H), 4.08 (qd, 1H, J = 6.5 and 6.4 Hz C5-H), 3.24 (m, 2H, C4-CH2-CH3), 1.79 (sext, 2 H, J = 7.4 Hz, C4-CH2-CH3), 1.47 (d, 3H, J = 6.6 Hz, C5-CH3), 1.15 (t, 3H, J = 7.3 Hz, C4-CH2-CH3) ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 183.48 (C-9), 179.45 (C-10), 162.15 (C-2), 154.70 (C-4), 139.93 (C-8a), 138.07 (C-9a), 126.13 (C-3), 124.07 (C-7), 114.26 (C-4a and C-10a), 107.00 (C-6), 36.60 (C4-CH2), 26.13 (C-5), 24.56 (C5-CH3), 23.28 (C4-CH2-CH2), 14.30 (C4-CH2-CH3) ppm.

3.3.14. 5,8-Dihydro-5-methyl-1-(4-tolyl)-1,8-diazaanthracene-2,9,10-trione (6v)

Method B: from 19 mg (0.07 mmol) of 8h and 16 mg (0.14 mmol) of 9e to yield 19 mg (80%) of 6v. [Found: C, 72.21; H, 4.96; N, 8.22. C20H16N2O3 requires C, 72.28; H, 4.85; N, 8.43]. Mp, 136–138 °C. νmax (KBr): 1641 (C=O) cm−1; 1H NMR (CDCl3, 250 MHz) δ: 8.01 (d, 1H, J = 9.6 Hz, C4-H), 7.28 (d, 2H, J = 7.9 Hz, C2′,6′-H), 6.97 (d, 2H, J = 7.3 Hz, C3′,5′-H), 6.79 (d, 2H, J = 9.6 Hz, C3-H y NH), 6.10 (dd, 1H, J = 7.7 and 4.4 Hz, C7-H), 4.92 (m, 1H, C6-H), 3.48–3.43 (m, 1H, C5-H), 2.42 (s, 3H, C4′-CH3), 0.98 (d, 3H, J = 6.6 Hz, C5-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 178.26 (C-9), 177.12 (C-10), 162.96 (C-2), 138.13 (C-1′), 137.58 (C-9a), 136.40 (C-8a), 134.50 (C-4′), 129.91 (C-3′, C-5′), 126.51 (C-4), 126.20 (C-2′, 6′), 123.48 (C-3), 122.02 (C-7), 114.07 (C-4a), 113.91 (C-10a), 110.72 (C-6), 26.06 (C-5), 23.88 (C5-CH3), 21.56 (C4′-CH3) ppm.

3.3.15. 5-Methyl-3-(4-tolyl)-1H-1,8-diazaanthracene-2,9,10-trione (5w)

Method B: from 10 mg (0.04 mmol) of 8i and 9 mg (0.10 mmol) of 9e to yield 8 mg (64%) of 5w. Found: C, 72.51; H, 4.37; N, 8.20. C20H14N2O3 requires C, 72.72; H, 4.27; N, 8.48]. 1HNMR (CDCl3, 250 MHz) δ: 9.62 (br s, 1H, NH), 8.85 (d, 1H, J = 4.9 Hz, C7-H), 8.22 (s, 1H, C4-H), 7.72 (d, 2H, J = 8.2 Hz, C2′,6′-H), 7.51 (d, 1H, J = 5.3 Hz, C6-H), 7.26 (d, 2H, J = 8.5 Hz, C3′,5′-H), 2.88 (s, 3H, C5-CH3), 2.39 (s, 3H, C4′-CH3) ppm.

3.3.16. 5,8-Dihydro-5-ethyl-4-methyl-1,8-diazaanthracene-2,9,10-trione (6ae)

[Found: C, 66.30; H, 5.30; N, 10.14. C15H14N2O3 requires C, 66.66; H, 5.22; N, 10.36]. Mp, 215–218 °C. νmax (KBr) 3403 (NH), 1658 (C=O) cm−1. 1H NMR (d6-DMSO, 250 MHz) δ: 9.72 (br s, 1H, NH), 6.99–6.88 (m, 1H, C3-H), 6.54–6.34 (m, 1H, C7-H), 6.36–6.33 (m, 1H, C6-H), 4.73 (br. s, 1H, C5-H), 2.40 (s, 3H, C4-CH3), 1.4–1.2 (m, 2H, C5-CH2), 0.75 (t, 3H, J = 7.5 Hz, C5-CH2-CH3) ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 183.97 (C-9), 177.21 (C-10), 162.24 (C-2), 150.86 (C-4), 139.67 (C-8a), 139.20 (C-9a), 127.08 (C-3), 125.33 (C-7), 112.81 (C-4a and C-10a), 106.52 (C-6), 32.36 (C-5), 30,68 (C5-CH2), 22.59 (C4-CH3), 9.57 (C5-CH2-CH3) ppm.

3.3.17. 5,8-Dihydro-4-methyl-5-propyl-1,8-diazaanthracene-2,9,10-trione (6af)

[Found: C, 67.13; H, 5.36; N, 9.45. C16H16N2O3 requires C, 67.59; H, 5.67; N, 9.85]. Mp, 190–192 °C. νmax (KBr) 3394 (NH), 1652 (C=O) cm−1. 1H NMR (d5-pyridine, 250 MHz) δ: 10.11 (br s, 1H, NH), 6.91 (s, 1H, C3-H), 6.71–6.69 (m, 1H, C7-H), 5.14–5.13 (m, 1H, C6-H), 4.13–4.00 (m, 1H, C5-H), 3.02 (br s, 2H, C5-CH2-), 2.77 (s, 3H, C4-CH3), 2.8–1.8 (m, 2H, C5-CH2-CH2), 1.05 (t, 3H, J = 7.1 Hz, C5-(CH2)2-CH3) ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 184.62 (C-9), 177.10 (C-10), 162.00 (C-2), 150.58 (C-4), 139.37 (C-8a), 138.70 (C-9a), 126.75 (C-3), 124.80 (C-7), 116.50 and 113.96 (C-4a and C-10a), 107.04 (C-6), 41.28 (C5-CH2), 31.60 (C-5), 23.26 (C4-CH3), 19.18 (C5-CH2-CH2-), 15.04 (C5-(CH2)2-CH3) ppm.

3.3.18. 5,8-Dihydro-5-butyl-4-methyl-1H-1,8-diazaanthracene-2,9,10-trione (6ag)

[Found: C, 68.12; H, 5.79; N, 9.02. C17H18N2O3 requires C, 68.44; H, 6.08; N, 9.39]. Mp, 190–191 °C. νmax (KBr) 3390 (NH), 1657 (C=O) cm−1. 1H NMR (d6-DMSO, 250 MHz) δ: 11.80 (br s, 1H, NH), 6.52 (s, 1H, C3-H), 6.19–6.17 (m, 1H, C7-H), 4.9–4.8 (m, 1H, C6-H), 3.51–3.48 (m, 1H, C5-H), 2.74 (s, 3H, C4-CH3), 1.4–1.0 (m, 9H, C5-(CH2)2-CH3) ppm. 13C NMR (d5-pyridine, 63 MHz) δ: 183.66 (C-9), 177.00 (C-10), 161.92 (C-2), 150.56 (C-4), 139.42 (C-8a), 138.73 (C-9a), 127.82 (C-3), 126.75 (C-7), 116.50 and 113.02 (C-4a and C-10a), 106.10 (C-6), 37.80 (C5-CH2), 30.73 (C-5), 27.12 (C5-CH2-CH2-), 22.75 (C5-(CH2)2-CH2-), 22.28 (C4-CH3), 13.75 (C5-(CH2)3-CH3) ppm.

3.4. Diels–Alder Reaction with Chiral 1-Dialkylamino-1-Azadienes—General Procedure

A solution of quinone 8c (50 mg, 0.02 mmol) and suitable azadiene 12c or 12b (1.1 eq.) in chloroform (5 mL) was refluxed for 3.5 h. The solution was evaporated, and the residue was chromatographed on silica gel eluting with a gradient from dichloromethane to dichloromethane-ethyl acetate mixture (6:4) yielding products 6ai (40%, 85% ee) and 6aj (30%, 83% ee).

3.4.1. (5R)-1,4,5-Trimethyl-5,8 Dihydro-1H-1,8-diazaanthracene-2,9,10-trione (6ai)

[Found: C, 66.83; H, 5.43; N, 9.96. C15H14N2O3 requires: C, 66.66; H, 5.22; N, 10.36]. Mp, 165–167 °C. νmax (KBr): 3247.7 (NH), 1664.1 (C=O) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 6.67 (s, 1H, C3-H), 6.49 (br s, 1H, C8-H), 6.13 (dd, 1H, J = 7.7 and 4.4 Hz, C7-H), 4.89 (t, 1H, J = 6.7 Hz, C6-H), 3.84 (s, 3H, N1- CH3), 3.64 (m, 1H, C5-H), 2.57 (s, 3H, C4-CH3), 1.12 (d, 3H, J = 6.6 Hz, C5-CH3) ppm. 13C NMR (CDCl3, 63 MHz) δ: 183.39 (C-9), 177.92 (C-10), 161.97 (C-2), 149.56 (C-4), 139.14 (C-8a), 137.48 (C-9a), 127.02 (C-3), 122.86 (C-7), 118.41 (C-4a), 114.22 (C-10a), 108.88 (C-6), 34.20 (N1-CH3), 26.29 (C-5), 25.78 (C4-CH3), 24.39 (C5-CH3) ppm.

3.4.2. (5S)-1,4,5-Trimethyl-5,8 Dihydro-1H-1,8-diazaanthracene-2,9,10-trione (6aj)

The spectroscopic data are identical to those of the compound 6ai.

3.5. Dehydrogenation of Dihydro Derivatives 6 to 1,8-Diazaanthracene-2,9,10-triones 5—General Procedures

Method A: To a solution of the suitable dihydro derivative 6 (0.01–0.20 mmol) in dichloromethane (1–10 mL) was added activated 85% MnO2 (5 eq–10 eq), the solution was stirred (10 min-24 h) at r.t. and then it was filtered through celite pad and washed twice with 30 mL of dichloromethane. The solvent was evaporated and, when necessary, chromatographed on silica gel, eluting with ethyl acetate, to afford compounds 6.
Method B: A solution of the suitable dihydro derivate 6 (0.06 to 0.30 mmol) in xylene (50–60 mL) was heated to reflux while a stream of air was bubbled through the solution. Xylene was added periodically to avoid complete evaporation of the solution. After the time indicated in each case, the solution was evaporated, and the crude was chromatographed on silica gel eluting with ethyl acetate to afford compounds 6.
Method C: A solution of NaOH 10% (2 mL) was added to the suitable dihydro derivative 6 (0.10 mmol). The suspension was stirred for 30 min at r.t., then it was diluted with 10 mL of water and extracted with ethyl acetate (3 × 20 mL). The resulting organic layer was evaporated and purified by chromatography on silica gel, eluting with ethyl acetate. The solid thus obtained was washed with ethyl ether to afford compounds 6.

3.5.1. 5-(p-(Dimethylamino)phenyl)-4-methyl-1H-1,8-diazaanthracene-2,9,10-trione (5i)

Method B: from 25 mg (0.07 mmol of 6i was obtained 20 mg (80%) of 5i. Reaction time 16 h;. [Found: C, 70.02; H, 4.72; N, 11.43. C21H17N3O3 requires C, 70.18; H, 4.77; N, 11.69]. Mp, >300 °C. νmax (KBr): 3440 (NH), 1676, 1664, 1656 (CO) cm−1. 1HNMR (CDCl3, 250 MHz) δ: 8.88 (d, 1H, J = 4.8 Hz, C7-H), 7.56 (d, 1H, J = 4.8 Hz, C6-H), 7.22 (d, 2H, J = 8.8 Hz, C2′,6′-H), 6.77 (d, 2H, J = 8.6 Hz, C3′,5′-H), 6.70 (d, 1H, J = 1.2 Hz, C3-H), 3.06 (s, 6H, N-CH3), 2.56 (d, 3H, J = 1.2 Hz, C4-CH3) ppm. 13C RMN (CDCl3, 63 MHz) δ: 182.21 (C-9), 177.14 (C-10), 167.94 (C-2), 160.39 (C-8a), 152.90 (C-7), 151.68 (C-5), 150.89 (C-4), 147.59 (C-4′), 138.64 (C-9a), 132.58 (C-6), 131.06 (C-1′), 129.56 (C-2′,C-6′), 128.96* (C-3), 128.58 (C-10a), 117.51 (C-4a), 111.84 (C-3′, C-5′), 40.35 (N-(CH3)2), 22.56 (C4-CH3) ppm.

3.5.2. 4,6-Dimethyl-5-propyl-1H-1,8-diazaanthracene-2,9,10-trione (5k)

Method A: from 20 mg of 6k (0.07 mmol) was obtained 18 mg (94%) of 5k. Reaction time: 5 min. [Found: C, 68.69; H, 5.32; N, 9.43. C17H16N2O3, requires C, 68.91; H, 5.44; N, 9.45]; Mp > 300 °C; νmax (KBr): 3421 (NH), 1654 (CO) cm−1; 1H NMR (CDCl3, 250 MHz) δ: 8,74 (s, 1H, C7-H), 6.70 (s, 1H, C3-H), 3.14 (t, 2H, J = 7.9, C5-CH2-CH2-CH3), 2.66 (s, 3H, C4-CH3), 2.49 (s, 3H, C6-CH3), 1.62 (m, 2H, C5-CH2-CH2-CH3), 1.10 (t, 3H, J = 7.3, C5-CH2-CH2-CH3) ppm. 13C RMN (CDCl3, 63 MHz) δ: 185.64 (C-9), 178.00 (C-10), 163.33 (C-2), 154.12 (C-5), 152.30 (C-4), 151.15 (C-7), 146.67 (C-8a), 140.67 (C-6), 136.13 (C-9a), 129.28 (C-3), 129.10 (C-10a), 117.95 (C-4a), 32.51 (C5-CH2), 30.10 (C6-CH3), 23.16 C5-CH2-CH2), 18.03 (C4-CH3), 15.28 (C5-CH2-CH2-CH3) ppm.

3.5.3. 3,4,5-Trimethyl-1H-1,8-diazaanthracene-2,9,10-trione (5r)

Method C: From 20 mg of 6r and 2 mL of NaOH 10% solution was obtained 74% of 5r. Reaction time: 5 min. [Found: C, 67.23; H, 4.34; N, 10.79. C15H12N2O3 requires C, 67.16; H, 4.51; N, 10.44]. Mp > 300 °C; νmax (KBr): 3432 (NH), 1633 (CO) cm−1; 1H NMR (CDCl3, 250 MHz) δ: 9,72 (br s, 1H, NH), 8.81 (d, 1H, J = 4.9 Hz, C7-H), 7.49 (d, 1H, J = 4.9 Hz, C6-H), 2.82 (s, 3H, C5-CH3), 2.63 (s, 3H, C4′-CH3), 2.26 (s, 3H, C3-CH3) ppm. 13C RMN (CDCl3, 63 MHz) δ: 183.88 (C-9), 172.58 (C-10), 160.63 (C-2), 152.91 (C-7), 151.01 (C-5), 146.86 (C-8a), 145.91 (C-4), 136.99 (C-9a), 136.05 (C-3), 132.38 (C-6), 129.62 (C-10a), 117.70 (C-4a), 22.55 (C5-CH3), 18.00 (C4-CH3), 13.18 (C3-CH3) ppm.

3.5.4. 4-Ethyl-5-methyl-1H-1,8-diazaanthracene-2,9,10-trione (5s)

Method B: From 16 mg of 6r was obtained 82% of 5s. Reaction time: 3 h. [Found: C, 67.12; H, 4.32; N, 10.43. C15H12N2O3 requires C, 67.16; H, 4.51; N, 10.44]. Mp, 222–224 °C (ethyl ether/ethanol, 8:2). νmax (KBr): 3428 (NH), 1546 (CO) cm−1; 1H NMR (CDCl3, 250 MHz) δ: 9,86 (br s, 1H, NH), 8.85 (d, 1H, J = 4.9 Hz, C7-H), 7.54 (d, 1H, J = 4.9 Hz, C6-H), 6.77 (s, 1H, C3-H), 3.14 (c, 2H, J = 7.3 Hz, C4-CH2-CH3), 2.86 (s, 3H, C5-CH3), 1.29 (t, 3H, J = 7.3 Hz, C4-CH2-CH3) ppm. 13C RMN (CDCl3, 63 MHz) δ: 183.19 (C-9), 177.08 (C-10), 160.53 (C-2), 157.44 (C-4), 153.19 (C-7), 151.44 (C-5), 146.98 (C-8a), 139.13 (C-9a), 132.76 (C-6), 129.45 (C-10a), 126.96 (C-3), 116.57 (C-4a), 27.90 (CH2-CH3), 22.94 (C5-CH3), 13.79 (CH2-CH3).

3.5.5. 5-Methyl-4-propyl-1H-1,8-diazaanthracene-2,9,10-trione (5t)

Method A: from 55 mg (0.19 mmol) of 6t and 99 mg (0.97 mmol) of activated 85% MnO2 was obtained 92% of 5t. Reaction time: 30 min. [Found: C, 67.88; H, 4.86; N, 9.75. C16H14N2O3 requires C, 68.08; H, 5.00; N, 9.92]. Mp: 236–238 °C. νmax (KBr): 3431 (NH), 1648 (CO) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 9.86 (br s, 1H, NH), 8.84 (d, 1H, J = 4.9 Hz, C7-H), 7.53 (d, 1H, J = 4.8 Hz, C6-H), 6.73 (s, 1H, C3-H), 3.06 (t, 2H, J = 7.4 Hz, C4-CH2), 2.86 (s, 3H, C5-CH3), 1.66 (m, 2H, J = 7.4 Hz, C4-CH2-CH2), 1.07 (t, 3H, J = 7.4 Hz, C4-CH2-CH2-CH3) ppm. 13C RMN (CDCl3, 63 MHz) δ: 183.08 (C-9), 176.92 (C-10), 160.61 (C-2), 155.80 (C-4), 153.08 (C-7), 151.38 (C-5), 147.07 (C-8a), 139.26 (C-9a), 132.61 (C-6), C-10a was not observed, 127.78 (C-3), 116.61 (C-4a), 36.50 (C4-CH2), 22.84 (C5-CH3), 22.76 (C4-CH2-CH2), 13.99 (C4-CH2-CH2-CH3) ppm.

3.5.6. 5-Methyl-1-(4-tolyl)-1,8-diazaanthracene-2,9,10-trione (5v)

Method A: from 30 mg 0.09 mmol) of 6v and 10 mg (0.09 mmol) of activated 85% MnO2 was obtained 3 mg (94%) of 5v Reaction time: 24 h. Yield, 94%. [Found: C, 72.42; H, 4.36; N, 8.21. C20H14N2O3 requires C, 72.72; H, 4.27; N, 8.48]. Mp, 260–262 °C; νmax (KBr) 1662 (CO) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 8.83 (d, 1H, J = 4.9 Hz, C7-H), 8.29 (d, 1H, J = 9.6 Hz, C4-H), 7.20 (d, 1H, J = 5.0 Hz, C6-H), 7.31 (d, 2H, J = 8.0 Hz, C3′,5′-H), 7.08 (d, 2H, J = 8.3 Hz, C2′,6′-H), 6.96 (d, 1H, J = 9.6 Hz, C3-H), 2.48 (s, 3H, C5-CH3), 2.45 (s, 3H, C4′-CH3) ppm. 13C RMN (CDCl3, 63 MHz) δ: 179.87 (C-9), 179.30 (C-10), 162.16 (C-2), 153.49 (C-7), 150.23 (C-5), 147.64 (C-8a), 138.73 (C-1′), 135.63 (C-9a), 135.26 (C-4), 130.78 (C-4′), 130.70 (C-6), 129.87 (C-3′, C-5′), 128.69 (C-10a), 126.87 (C-2′,C-6′), 126.42 (C-3), 117.81 (C-4a), 22.88 (C-5-CH3), 21.54 (C4′-CH3) ppm.

3.6. Diels–Alder Reaction of Quinone 8b and 2,3-Dimethyl-1,3-butadiene

Method A: A solution of quinone 8b (223 mg, 1.20 mmol) and 2,3-dimethyl-1,3-butadiene (0.15 mL, 1.30 mmol) in ethyl acetate was heated at 100 °C for 12 h in a sealed tube. The solution was cooled and evaporate under vacuum. The residue was chromatographed on silica gel eluting with dichloromethane/ethyl acetate (6:4), to afford 153 mg of (±)-(5aS*,9aR*)-4,7,8-trimethyl-5a,6,9,9a-tetrahydrobenzo[g]quinoline-2,5,10(1H)-trione 14 (48%). [Found: C, 70.21; H, 6.15; N, 5.07. C16H17NO3 requires: C, 70.83; H, 6.32; N, 5.16]. Mp, 285–288 °C (AcOEt). νmax (KBr): 3200–2800 (NH), 1660 (CO) cm−1. 1H NMR (CDCl3, 300 MHz) δ: 9.80 (br s, 1H, NH), 6.64 (d, 1H, J = 1.2 Hz, H-3); 3.33 (m, 2H, C8a-H and C10a-H), 2.53 (d, 3 H, J = 1.2 Hz, C4-CH3), 2.42 (m, 2H, C5-Hax and C8-Hax), 2.15 (m, 2H, C5-Heq and C8-Heq), 1.64 (s, 6H, C6,7-CH3) ppm. 13C NMR (CDCl3, 75 MHz) δ: 196.18 (C-9), 192.68 (C-10), 160.18 (C-2), 152.15 (C-4), 140.18 (C-9a), 127.86 (C-3), 123.68 (C-6), 123.18 (C-7), 118.20 (C-4a), 47.76 (C-8a), 46.09 (C-9a), 30.70 (C-5), 30.46 (C-8), 21.98 (C4-CH3), 18.82 (C6-CH3 and C7-CH3) ppm.
Method B: A solution of quinone 8b (245 mg, 1.30 mmol) and 2,3-dimethyl-1,3-butadiene (0.16 mL, 1.40 mmol) in ethyl acetate was heated at 120 °C for 88 h in a sealed tube. The solution was cooled and evaporated under vacuum. The residue was chromatographed on silica gel eluting with a gradient from dichloromethane to dichloromethane/ethyl acetate (6:4), to afford a mixture of compounds 14 and 7g (14:7g = 3.5:1). A solution of this mixture (90 mg, 0.22 mmol) and DDQ (340 mg, 1.50 mmol) in dry benzene (130 mL) was refluxed under nitrogen atmosphere for 7 h. The reaction mixture was evaporated, and the crude was chromatographed on silica gel eluting with dichloromethane/ethyl acetate (1:1) yielding 70 mg of compound 7g (68%). [Found: C, 71.50; H, 4.97; N, 5.25. C16H13NO3 requires: C, 71.90; H, 4.90; N, 5.24]. Mp > 310 °C (AcOEt/CH2Cl2 1:1). νmax (KBr): 3320, 3630–3070 (NH), 1685, 1670, 1660 (CO) cm−1. 1H NMR (CDCl3, 250 MHz) δ: 8.81 (s, 1H, C8-H), 8.09 (s, 1H, C5-H), 6.67 (d, 1H, J = 1. Hz, C3-H), 2.70 (d, 3 H, J = 1 Hz, C4-CH3), 2.45 (s, 3 H, C6- CH3), 2.43 (s, 3 H, C7-CH3) ppm.

3.7. Diels–Alder Reaction of Quinone 8b and Anthracene—Synthesis of 4-Methyl-6,11-[1,2]Benzenonaphtho[2,3-g]Quinoline-2,5,12(1H,6H,11H)-trione 16

A solution of quinone 8b (17 mg, 0.94 mmol) and anthracene (184 mg, 1.03 mmol) in chloroform (100 mL) was refluxed for 16 h. The solution was cooled and evaporated under vacuum. The residue was chromatographed on silica gel eluting with a gradient from dichloromethane to dichloromethane/ethyl acetate (7:3), to yield 163 mg (49%) of compound 16. [Found: C, 78.54; H, 4.21; N, 3.88. C24H15NO3 requires: C, 78.89; H, 4.14; N, 3.83]. Mp, 306–308 °C (AcOEt). νmax (KBr): 1650, 1630 (CO) cm−1. 1H NMR (d6-DMSO, 300 MHz) δ: 10.86 (br s, 1H, NH), 7.52 (m, 4H, anthracene), 7.05 (m, 4H, anthracene), 6.46 (d, 1H, J = 1.2 Hz, H-3); 5.96 and 5.94 (2s, 2H, C9′-H and C10′-H), 2.46 (d, 3H, J = 1.2 Hz, C4-CH3) ppm. 13C NMR (d6-DMSO, 75 MHz) δ: 180.45 (C-8), 175.97 (C-5), 161.92 (C-2), 155.46 (C-6), 151.64 (C-4), 149.46 (C-7), 143.08 (C-4a′, C-8a′, C-9a′, C-10a′), 138.58 (C-8a), 126.39 (C-3), 125.78 and 125.71 (C1′, C-4′, C-5′, C-8′), 124.55 and 124.39 (C-2, C-3, C-6, C-7), 113.25 (C-4a), 47.72 (C-9′), 47.05 (C-10′), 22.25 (C4-CH3) ppm.

3.8. Diels–Alder Reaction of Quinone 8b and Cyclopentadiene

A solution of quinone 8b (370 mg, 1.90 mmol) and cyclopentadiene (0.32 mL, 3.90 mmol) in chloroform (130 mL) was heating at 110 °C for 18 h in a sealed tube. The solution was cooled and evaporated under vacuum. The residue was chromatographed on silica gel eluting with a gradient from dichloromethane to dichloromethane/ethyl acetate (1:1), to yield 40 mg of compound 17 (23%) and 118 mg of compound 18 (71%).

3.8.1. 9,10-Dihydroxy-5,8-methano-4-methyl-5,8-dihydro-1H-1-azaanthracen-2-one (17)

[Found: C, 70.29; H, 4.98; N, 5.25. C15H13NO3 requires C, 70.58; H, 5.13; N, 5.49]. Mp, 323–326 °C (AcOEt). νmax (KBr): 3325, 3300–2600 (OH), 1625 (CO) cm−1. 1H NMR (d6-DMSO, 300 MHz) δ: 9.68 (br s, 1H, OH), 9.21 (br s, 1H, OH), 8.81 (br s, 1H, NH), 6.72 (m, 2H, H-6 and H-7), 6.11 (s, 1H, H-3), 4.30 (d, 2H, J = 10 Hz, H-5, H-8); 2.40 (s, 3H, C4-CH3), 2.00 (m, 2H, C5-CH2-C8) ppm. 13C NMR (d6-DMSO, 75 MHz) δ: 160.84 (C-2), 150.21 (C-10), 142.82 (C-6), 141.69 (C-9), 141.32 (C-7), 137.79 (C-8a), 130.76 (C-4), 129.16 (C-10a), 127.85 (C-9a), 119.29 (C-3), 108.86 (C-4a), 66.38 (C5-CH2-C8), 46.80 (C-5), 45.96 (C-8), 24.39 (C4-CH3) ppm.

3.8.2. 5,8-Methano-4-methyl-5,8-dihydro-1H-1-azaanthracen-2,9,10-trione (18)

[Found: C, 70.89; H, 4.18; N, 5.35. C15H11NO3 requires C, 71.14; H, 4.38; N, 5.53]. Mp, 323–236 °C (AcOEt). νmax (KBr): 3200–2800 (NH), 1655, 1650, 1640 (CO) cm−1. 1H NMR (CDCl3, 300 MHz) δ: 10.36 (br s, 1H, NH), 6.88 (m, 2H, H-6 and H-7), 6.59 (d, 1H, J = 1.2 Hz, H-3), 4.20 (br s, 2H, H-5, H-8); 2.58 (d, 3H, J = 1.2 Hz, C4-CH3), 2.36 (m, 2H, C5-CH2-C8) ppm. 13C NMR (CDCl3, 75 MHz) δ: 181.02 (C-9), 175.37 (C-10), 165.58 (C-10a), 161.07 (C-2), 157.09 (C-8a), 151.08 (C-4), 142.37 (C-6), 142.31 (C-7), 139.25 (C-9a), 125.69 (C-3), 113.42 (C-4a), 73.41 (C5-CH2-C8), 48.98 (C-5), 48.20 (C-8), 22.09 (C4-CH3) ppm.

3.9. Bioassays

Cells (Sigma-Aldrich, Madrid, Spain or ATCC, Manassas, Virginia, USA) were maintained in logarithmic growth phase in Eagle’s essential medium with Earle’s balanced salts, 2.0 mM L-glutamine, non-essential amino acids and no sodium bicarbonate (EMEM/NEAA), supplemented with 10% sodium bicarbonate 10–2 fetal calf serum (FCS) and 0.1 g/L penicillin G + streptomycin sulphate.
To determine and compare the antitumor activity of these compounds, simple screening procedures were performed using an adapted form of the method described by Bergerom et al. [56,57] The tumor cells used were P-388 (BDA/2 mouse lymphoid neoplasm suspension culture), A-549 (human lung carcinoma monolayer culture), HT-29 (human colon carcinoma monolayer culture), MEL-29 (human melanoma monolayer culture).
P-388 cells were seeded in 16 mm wells at 1 × 104 cells per well in aliquots to 1 mL of 5FCS MEM containing the indicated drug concentration. Separately, a batch of drug-free cultures was seeded as a growth control to ensure that the cells remained in log phase of growth. All determinations were performed in triplicate. After three days of incubation at 37 °C, 10% CO2 in an atmosphere of 98% humidity, the approximate IC50 was determined by comparing growth in the drug wells and growth in the control wells.
A-549, HT-29 and MEL-28 cells were seeded in 16 mm wells at 2 × 104 cells per well in 1 mL aliquots of MEM 10FCS containing the indicated drug concentration. Separately, a drug-free culture batch was seeded as a growth control to ensure that the cells remained in log phase of growth. All determinations were performed in duplicate. After three days of incubation at 37 °C, 10% CO2 in an atmosphere of 98% humidity, the wells were stained with 0.1% Crystal Violet. The IC50 value was determined by comparing the growth in the drug wells and the growth in the control wells.

4. Conclusions

The synthesis of libraries of derivatives of the 1,8-diazaanthracene-2,9,10-trione, including their 5,8-dihydro derivatives, 1,8-diazaanthracene-2,7,9,10-tetraone and 1-azaanthracene-2,9,10-trione frameworks, structurally related to the diazaquinomycin and marcanine families of natural products, was achieved using Diels–Alder strategies. Many of them were found to have potent and selective cytotoxicity against some solid tumors. In particular, 1,8-diazaanthracene-2,9,10-triones and their 5,8-dihydro derivatives were particularly active against a human lung cancer cell line. The use of a 1-azadiene comprising a SAMP-related chiral auxiliary allowed the enantioselective synthesis of two representatives of chiral 5-substituted 1,8-diazaanthracene-2,9,10-triones, and their study showed that their cytotoxicity was not enantiospecific. The following targets and processes were discarded as explanations of the mechanism of action of our compounds: thymidylate synthase, dihydrofolate reductase, topoisomerases I and II, ADN polymerases, ARN polymerases, DNA, RNA and protein synthesis. Further mechanistic work will be needed to characterize the mechanism of action of these interesting compounds.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules29020489/s1, Table S1: Cytotoxicity of quinolinetriones 8. Table S2: Cytotoxicity of 1-azaanthracenetrione derivatives 7 and the related non-aromatic intermediate 14. Table S3: Cytotoxicity of 5,8-dihydro-1-azaanthracenetrione derivatives 15, 16 and 18. Table S4: Cytotoxicity of compounds 5. Table S5: Cytotoxicity of compounds 6. Table S6: Cytotoxicity of the diazoquinomycin derivatives 1. Copies of representative NMR spectra.

Author Contributions

Conceptualization, C.A. and J.C.M.; methodology, P.L.-A., J.M.P., E.P.-A. and M.Á.A.; data curation, M.R.-S.; writing—original draft preparation, J.C.M.; writing—review and editing, C.A., J.C.M. and M.R.-S.; supervision, C.A. and J.C.M.; funding acquisition, C.A. and J.C.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Ministerio de Ciencia e Innovación, Spain, grant number TED2021-129408B-I00. The APC was not funded.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the article and supplementary materials.

Acknowledgments

We thank PharmaMar for the cytotoxicity assays.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Dulo, B.; Phan, K.; Githaiga, J.; Raes, K.; De Meeste, S. Natural quinone dyes: A review on structure, extraction techniques, analysis and application potential. Waste Biomass Valor. 2021, 12, 6339–6374. [Google Scholar] [CrossRef]
  2. Malik, M.S.; Alsantali, R.I.; Jassas, R.S.; Alsimaree, A.A.; Syed, R.; Alsharif, M.A.; Kalpana, K.; Morad, M.; Althagafia, I.I.; Ahmed, S.A. Journey of anthraquinones as anticancer agents—A systematic review of recent literature. RSC Adv. 2021, 11, 35806. [Google Scholar] [CrossRef] [PubMed]
  3. Martins-Teixeira, M.B.; Carvalho, I. Antitumor anthracyclines: Progress and perspectives. Chem. Med. Chem. 2020, 15, 933–948. [Google Scholar] [CrossRef]
  4. Moiseeva, A.A. Anthracycline derivatives and their anticancer activity. INEOS Open 2019, 2, 9–18. [Google Scholar] [CrossRef]
  5. Shandukya, M.; Sharma, S.; Prasad Das, P.; Charak, S. Molecular-level understanding of the anticancer action mechanism of anthracyclines. In Advances in Precision Medicine Oncology; Arnouk, H., Hassan, B.A.R., Eds.; Intech Open: London, UK, 2020; Chapter 9. [Google Scholar] [CrossRef]
  6. Hasen, M.R.; Hurley, L.H. Pluramycins. Old drugs having modern friends in structural biology. Acc. Chem. Res. 1996, 29, 249–258. [Google Scholar] [CrossRef]
  7. Kitamura, K.; Ando, Y.; Matsumoto, T.; Suzuki, K. Synthesis of the pluramycins 1: Two designed anthrones as enabling platforms for flexible bis-C-glycosylation. Angew. Chem. Int. Ed. 2014, 53, 1258–1261. [Google Scholar] [CrossRef] [PubMed]
  8. Kitamura, K.; Maezawa, Y.; Ando, Y.; Kusumi, T.; Matsumoto, T.; Suzuki, K. Synthesis of the pluramycins 2: Total synthesis and structure assignment of saptomycin B. Angew. Chem. Int. Ed. 2014, 53, 1262–1265. [Google Scholar] [CrossRef]
  9. Gredicak, M.; Jerik, I. Enediyne compounds—New promises in anticancer therapy. Acta Pharm. 2007, 57, 133–150. [Google Scholar] [CrossRef]
  10. Nicolaou, K.C.; Smith, A.L. The enediyne antibiotics. J. Med. Chem. 1996, 39, 2103–2117. [Google Scholar] [CrossRef]
  11. Krapcho, A.P.; Maresch, M.J.; Hacker, M.P.; Menta, E.; Oliva, A.; Giuliani, F.C.; Spinelli, S. Aza and diaza bioisosteric anthracene-9,10-diones as antitumor agents. Acta Biochem. Polon. 1995, 42, 427–432. [Google Scholar] [CrossRef]
  12. Krapcho, A.P.; Maresch, M.J.; Hacker, M.P.; Hazelhurst, L.; Menta, E.; Oliva, A.; Spinelli, S.; Beggiolin, G.; Giuliani, F.C.; Pezzoni, G.; et al. Anthracene-9,10-diones and aza bioisosteres as antitumor agents. Curr. Med. Chem. 1995, 2, 803–824. [Google Scholar] [CrossRef]
  13. Bair, J.S.; Palchaudhuri, R.; Hergenrother, P.J. Chemistry and biology of deoxynyboquinone, a potent inducer of cancer cell death. J. Am. Chem. Soc. 2010, 132, 5469–5478. [Google Scholar] [CrossRef] [PubMed]
  14. Parkinson, E.I.; Hergenrother, P.J. Deoxy-nyboquinones as NQO1-activated cancer therapeutics. Acc. Chem. Res. 2015, 48, 2715–2733. [Google Scholar] [CrossRef] [PubMed]
  15. Forbis, R.M.; Rinehart, R.L. Nybomycin VII. Preparative routes to nybomycin and deoxynybomycin. J. Am. Chem. Soc. 1973, 95, 500–5013. [Google Scholar] [CrossRef]
  16. Lee, H.; Anderson, W.K. Total synthesis of of 4-acetyloxymethyl-1,6,9-trimethyl-1,-9-diazaanthracene-2,5,8,10-tetraone, a nybomycin acetate analogue. Tetrahedron Lett. 1990, 31, 4405–4408. [Google Scholar] [CrossRef]
  17. Ōmura, S.; Iwai, Y.; Hinotozawa, K.; Tanaka, H.; Takahashi, Y.; Nakagawa, A. OM-704 A, a new antibiotic active against gram-positive bacteria produced by Streptomyces sp. J. Antibiot. 1982, 35, 1425–1429. [Google Scholar] [CrossRef] [PubMed]
  18. Ōmura, S.; Nakagawa, A.; Aoyama, H.; Hinotozawa, K.; Sano, H. The structures of diazaquinomycins A and B, new antibiotic metabolites. Tetrahedron Lett. 1983, 24, 3643–3646. [Google Scholar] [CrossRef]
  19. Ōmura, S.; Murata, M.; Kimura, K.; Matsukura, S.; Nishihara, T.; Tanaka, H. Screening for new antifolates of microbial origin and a new antifolate AM-8402. J. Antibiot. 1985, 38, 1016–1024. [Google Scholar] [CrossRef]
  20. Murata, M.; MiYasaka, T.; Tanaka, H.; Omura, S. Diazaquinomycin A, a new antifolate antibiotic, inhibits thymidylate synthase. J. Antibiot. 1985, 38, 1025–1033. [Google Scholar] [CrossRef]
  21. Mullowney, M.W.; ÓhAinmhire, E.; Shikh, A.; Wei, X.; Tanouye, U.; Santarsiero, B.D.; Burdette, J.; Murphy, B.T. Diazaquinomycins E-G, novel diaza-anthracene analogs from a marine-derived Streptomyces sp. Mar. Drugs 2014, 12, 3574–3586. [Google Scholar] [CrossRef]
  22. Mullowney, M.W.; Hwang, C.H.; Newsome, A.G.; Wei, X.; Tanouye, U.; Wan, B.; Carlson, S.; Barranis, N.J.; hAinmhire, E.O.; Chen, W.-L.; et al. Diaza-anthracene antibiotics from freshwater-derived actinomycete with selective antibacterial activity toward Mycobacterim tuberculosis. ACS Infect. Dis. 2015, 1, 168–174. [Google Scholar] [CrossRef] [PubMed]
  23. Braesel, J.; Lee, J.-H.; Arnould, B.; Murphy, B.T.; Eustáquio, A.S. Diazaquinomycin biosynthetic gene clusters from marine and freshwater actinomycetes. J. Nat. Prod. 2019, 82, 937–946. [Google Scholar] [CrossRef] [PubMed]
  24. Soonthornchareonnon, N.; Suwanborirux, K.; Bavovada, R.; Patarapanich, C.; Cassady, J.M. New cytotoxic 1-azaanthraquinones and 3-aminonapthoquinone from the stem bark of Goniothalamus marcanii. J. Nat. Prod. 1999, 62, 1390–1394. [Google Scholar] [CrossRef]
  25. Thanuphol, P.; Asami, Y.; Shiomi, K.; Wongnoppavich, A.; Tuchinda, P.; Soonthornchareonnon, N. Marcanine G, a new cytotoxic 1-azaanthraquinone from the stem bark of Goniothalamus marcanii Craib. Nat. Prod. Res. 2018, 32, 1682–1689. [Google Scholar] [CrossRef]
  26. Roumy, V.; Fabre, N.; Souard, F.; Massou, S.; Bourdy, G.; Maurel, S.; Valentin, A.; Moulis, C. Isolation and antimalarial activity of alkaloids from Pseudoxandra cuspidate. Planta Med. 2006, 72, 894–898. [Google Scholar] [CrossRef]
  27. Ichino, C.; Soonthornchareonnon, N.; Chuakul, W.; Kiyohara, H.; Ishiyama, A.; Sekiguchi, H.; Namatame, M.; Otoguro, K.; Ōmura, S.; Yamada, H. Screening of Thai medicinal plant extracts and their active constituents for in vitro antimalarial activity. Phytother. Res. 2006, 20, 307–309. [Google Scholar] [CrossRef]
  28. Jacobs, N.; Lang, S.; Panisch, R.; Wittstock, G.; Groth, U.; Nasiria, H.R. Investigation on the electrochemistry and cytotoxicity of the natural product marcanine A and its synthetic derivates. RSC Adv. 2015, 5, 58561–58565. [Google Scholar] [CrossRef]
  29. Thanuphol, T.; Noulsri, E.; Suwanborirux, K.; Soonthornchreannon, N.; Pattanapanyasal, K. Cytotoxic activity of marcanine C and some other aminoquinone derivates against MCF-7 cells. Mahidol Univ. J. Pharm. Sci. 2019, 43, 203–210. [Google Scholar] [CrossRef]
  30. Tsuzuki, K.; Yokozuka, T.; Murata, M.; Tanaka, H.; Ōmura, S. Synthesis and biological activity of analogues of diazaquinomycin A, a new thymidylate synthase inhibitor. J. Antibiot. 1989, 42, 727–737. [Google Scholar] [CrossRef]
  31. Gesto, C.; De la Cuesta, E.; Avendaño, C.; Emling, F. Synthesis and biological activity of new 1,8-diaza-2,9,10-anthracenetrione derivatives. J. Pharm. Sci. 1992, 8, 815–816. [Google Scholar] [CrossRef]
  32. Ramos, M.T.; Díaz-Guerra, L.M.; García-Copín, S.; Avendaño, C.; García-Grávalos, D.; De Quesada, T. Synthesis and Antitumor activity of fluorinated 1-aza and 1,8-diazaantraquinones. Il Farmaco 1996, 51, 375–379. [Google Scholar] [CrossRef] [PubMed]
  33. Pérez, J.M.; Avendaño, C.; Menéndez, J.C. 1-Acylamino-1-azadienes as an alternative to 1-dimethylamino-1-azadienes in the preparation of 1,8-diazaanthracene-2,9,10-triones. Tetrahedron 1995, 51, 6573–6586. [Google Scholar] [CrossRef]
  34. Pérez, J.M.; López-Alvarado, P.; Alonso, M.A.; Avendaño, C.; Menéndez, J.C. Silica gel-supported hetero Diels-Alder reactions of quinolinetriones. Tetrahedron Lett. 1996, 37, 6955–6958. [Google Scholar] [CrossRef]
  35. Pascual-Alfonso, E.; Avendaño, C.; Menéndez, J.C. Improvements in the hetero Diels-Alder reactions of 1-dimethylamino-1-azadienes in the presence of an electrophilic scavenger resin. Synlett 2000, 2000, 205–208. [Google Scholar] [CrossRef]
  36. Blanco, M.M.; Alonso, M.A.; Avendaño, C.; Menéndez, J.C. New findings in hetero Diels-Alder reactions of quinolinetriones. Tetrahedron 1996, 52, 5933–5944. [Google Scholar] [CrossRef]
  37. Villacampa, M.; Pérez, J.M.; Avendaño, C.; Menéndez, J.C. Ultrasound assisted Diels-Alder reactions of 1-azadienes with “normal” electronic demand. Tetrahedron 1994, 50, 10047–10054. [Google Scholar] [CrossRef]
  38. Waldner, A. [4+2]-Cycloadditionen von α,β-ungesättigten Hydrazonen. Teil 2. Pyridin-2,3-dicarboximide aus 1,4-Dihydropyridin-Derivaten. Helv. Chim. Acta 1988, 71, 493–497. [Google Scholar] [CrossRef]
  39. Echavarren, A. Lewis acid catalyzed reactions of α,β-Unsaturated N,N-dimethylhydrazones with 1,4-benzoquinone. Formation of indoles by a novel oxidative rearrangement. J. Org. Chem. 1990, 55, 4255–4260. [Google Scholar] [CrossRef]
  40. Satsumabayashi, S.; Nakajo, K.; Soneda, R.; Motoki, S. Preparation of Some α,β-Unsaturated Aldehydes. Bull. Chem. Soc. Jap. 1970, 43, 1586. [Google Scholar] [CrossRef]
  41. López-Alvarado, P.; Avendaño, C.; Menéndez, J.C. A General synthesis of quinoline-2,5,8 (1H)-trione via acylation of 2,5-dimethoxyaniline with S-tert-butyl thioacetates by application of the Knorr Cyclization. Synthesis 1998, 1998, 186–194. [Google Scholar] [CrossRef]
  42. Gesto, C.; De la Cuesta, E.; Avendaño, C. A Comparative study of synthetic approaches to 1-methyl-2,5,8(1H)-quinolinetrione and 4-methyl-2,5,8(1H)-quinolinetrione. Synthesis 1991, 1991, 727–730. [Google Scholar] [CrossRef]
  43. Pettit, G.R.; Fleming, W.C.; Paull, K.D. Synthesis of the 6- and 7-hydroxy-5,8-dioxocarbostyrils. J. Org. Chem. 1968, 33, 1089–1092. [Google Scholar] [CrossRef] [PubMed]
  44. Pérez, J.M.; López-Alvarado, P.; Pascual-Alfonso, E.; Avendaño, C.; Menéndez, J.C. Concise preparation of 1,8-diazaanthracene-2,7,9,10-tetraones. Two alternative syntheses of the natural antifolate diazaquinomycin A. Tetrahedron 2000, 56, 4575–4583. [Google Scholar] [CrossRef]
  45. Alonso, M.A.; Blanco, M.M.; Avendaño, C.; Menéndez, J.C. Synthesis of 2,5,8(1H)-quinolinetrione derivatives through Vilsmeier-Haack formylation of 2,5-dimethoxyanilides. Heterocycles 1993, 36, 2315–2325. [Google Scholar] [CrossRef]
  46. Gesto, C.; De la Cuesta, E.; Avendaño, C. Synthesis of diaza-anthraquinones by hetero Diels-Alder cycloaddition reactions. Tetrahedron 1989, 45, 4477–4484. [Google Scholar] [CrossRef]
  47. Enders, D.; Kipphardt, H.; Gerdes, P.; Breña-Valle, L.J.; Bhunsan, V. Large scale preparation of versatile chiral auxiliaries derived from (S)-proline. Bull. Soc. Chim. Belg. 1988, 97, 691. [Google Scholar] [CrossRef]
  48. Beaudgnies, R.; Ghosez, L. Asymmetric Diels-Alder reactions with chiral 1-azadienes. Tetrahedron Asymmetry 1994, 5, 557–560. [Google Scholar] [CrossRef]
  49. Pérez, J.M.; Vidal, L.; Grande, M.T.; Menéndez, J.C.; Avendaño, C. Regioselectivity of the Diels-Alder reaction of 2,5,8 (1H)-quinolinetriones. Tetrahedron 1994, 50, 7923–7932. [Google Scholar] [CrossRef]
  50. Kelly, T.R.; Field, J.A.; Li, Q. Synthesis of diazaquinomycin A and B: The first double Knorr cyclization. Tetrahedron Lett. 1988, 29, 3545–3546. [Google Scholar] [CrossRef]
  51. Prior, A.M.; Sun, D. Total synthesis of diazaquinomycins H and J using double Knorr cyclization in the presence of triisopropylsilane. RSC Adv. 2019, 9, 1759–1771. [Google Scholar] [CrossRef]
  52. Kovacic, P.; Osuna, J.A. Mechanisms of anti-cancer agents: Emphasis on oxidative stress and electron transfer. Curr. Pharm. Des. 2000, 6, 277–309. [Google Scholar] [CrossRef] [PubMed]
  53. Yang, Y.; Karakhanova, S.; Werner, J.; Bazhin, A.V. Reactive oxygen species in cancer biology and anticancer therapy. Curr. Med. Chem. 2013, 20, 3677–3692. [Google Scholar] [CrossRef]
  54. Denmark, S.E.; Edwards, J.P.; Weber, T.; Piotrowski, D.W. Organocerium additions to proline-derived hydrazones: Synthesis of enantiomerically enriched amines. Tetrahedron Asymmetry 2010, 21, 1278–1302. [Google Scholar] [CrossRef]
  55. Beebe, X.; Schore, N.E.; Kurth, M.J. Polymer-supported synthesis of cyclic ethers: Electrophilic cyclization of isoxazolines. J. Org. Chem. 1995, 60, 4196. [Google Scholar] [CrossRef]
  56. Bergeron, R.J.; Gavanaugh, P.F., Jr.; Kline, S.J.; Hughes, R.G., Jr.; Elliott, G.T.; Porter, C.W. Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. Biochem. Bioph. Res. Comm. 1984, 121, 848–854. [Google Scholar] [CrossRef]
  57. Schroeder, A.C.; Hughes, R.G.; Bloch, A. Synthesis and biological effects of acyclic pyrimidine nucleoside analogs. J. Med. Chem. 1981, 24, 1078–1083. [Google Scholar] [CrossRef]
Molecules 29 00489 g001
Figure 1. Structures of the diazaquinomycins, deoxynyboquinones, and marcanines.
Figure 1. Structures of the diazaquinomycins, deoxynyboquinones, and marcanines.
Molecules 29 00489 g001
Molecules 29 00489 g002
Figure 2. Diazaquinomycin derivatives prepared by Ōmura (3 and 4) and compounds 5, 6, 7, and 8 studied here.
Figure 2. Diazaquinomycin derivatives prepared by Ōmura (3 and 4) and compounds 5, 6, 7, and 8 studied here.
Molecules 29 00489 g002
Molecules 29 00489 sch001
Scheme 1. Hetero Diels–Alder reaction between azadienes 9 and quinones 8.
Scheme 1. Hetero Diels–Alder reaction between azadienes 9 and quinones 8.
Molecules 29 00489 sch001
Molecules 29 00489 sch002
Scheme 2. The hetero Diels–Alder reaction of azadiene 9b and quinone 8f.
Scheme 2. The hetero Diels–Alder reaction of azadiene 9b and quinone 8f.
Molecules 29 00489 sch002
Molecules 29 00489 sch003
Scheme 3. A mixture of 1,5-diaza- and 1,8-diaza-regioisomers was isolated in the reaction of the N-aryl quinolinetrione 8h with azadiene 9b.
Scheme 3. A mixture of 1,5-diaza- and 1,8-diaza-regioisomers was isolated in the reaction of the N-aryl quinolinetrione 8h with azadiene 9b.
Molecules 29 00489 sch003
Molecules 29 00489 sch004
Scheme 4. Synthesis of enantio-enriched compound 6ai and its enantiomer 6aj. The chiral 1-aminopyrrolidine derivatives were obtained according to reference [47].
Scheme 4. Synthesis of enantio-enriched compound 6ai and its enantiomer 6aj. The chiral 1-aminopyrrolidine derivatives were obtained according to reference [47].
Molecules 29 00489 sch004
Molecules 29 00489 sch005
Scheme 5. Dehydrogenation of dihydro derivatives 6.
Scheme 5. Dehydrogenation of dihydro derivatives 6.
Molecules 29 00489 sch005
Molecules 29 00489 sch006
Scheme 6. Diels–Alder reactions of dienes 13 and quinones 8.
Scheme 6. Diels–Alder reactions of dienes 13 and quinones 8.
Molecules 29 00489 sch006
Molecules 29 00489 sch007
Scheme 7. Synthesis of the 1-azaanthracenetrione derivative 7g.
Scheme 7. Synthesis of the 1-azaanthracenetrione derivative 7g.
Molecules 29 00489 sch007
Molecules 29 00489 sch008
Scheme 8. Synthesis of 5,8-dihydro-1-azaanthracenetrione derivatives.
Scheme 8. Synthesis of 5,8-dihydro-1-azaanthracenetrione derivatives.
Molecules 29 00489 sch008
Molecules 29 00489 g003
Figure 3. Cytotoxicity of quinolinetriones 8. Numerical data can be found in Table S1 (Supporting Information).
Figure 3. Cytotoxicity of quinolinetriones 8. Numerical data can be found in Table S1 (Supporting Information).
Molecules 29 00489 g003
Molecules 29 00489 g004
Figure 4. Cytotoxicity of 1-azaanthracenetrione derivatives 7, the related non-aromatic intermediate 14 and 5,8-dihydro-1-azaanthracenetrione derivatives 15, 16, and 18. Numerical data can be found in Tables S2 and S3 (Supporting Information).
Figure 4. Cytotoxicity of 1-azaanthracenetrione derivatives 7, the related non-aromatic intermediate 14 and 5,8-dihydro-1-azaanthracenetrione derivatives 15, 16, and 18. Numerical data can be found in Tables S2 and S3 (Supporting Information).
Molecules 29 00489 g004
Molecules 29 00489 g005
Figure 5. Cytotoxicity of 1,8-diazaanthracenetriones 5a–5j. Numerical data can be found in Table S4 (Supporting Information).
Figure 5. Cytotoxicity of 1,8-diazaanthracenetriones 5a–5j. Numerical data can be found in Table S4 (Supporting Information).
Molecules 29 00489 g005
Molecules 29 00489 g006
Figure 6. Cytotoxicity of 1,8-diazaanthracenetriones 5k–5t. Numerical data can be found in Table S4 (Supporting Information).
Figure 6. Cytotoxicity of 1,8-diazaanthracenetriones 5k–5t. Numerical data can be found in Table S4 (Supporting Information).
Molecules 29 00489 g006
Molecules 29 00489 g007
Figure 7. Cytotoxicity of 1,8-diazaanthracenetriones 5u–5ah. Numerical data can be found in Table S4 (Supporting Information).
Figure 7. Cytotoxicity of 1,8-diazaanthracenetriones 5u–5ah. Numerical data can be found in Table S4 (Supporting Information).
Molecules 29 00489 g007
Molecules 29 00489 g008
Figure 8. Cytotoxicity of compound 12 (IC50, µM).
Figure 8. Cytotoxicity of compound 12 (IC50, µM).
Molecules 29 00489 g008
Molecules 29 00489 g009
Figure 9. Cytotoxicity of 5,8-dihydro-1,8-diazaanthracenetriones 6g–6t. Numerical data can be found in Table S5 (Supporting Information).
Figure 9. Cytotoxicity of 5,8-dihydro-1,8-diazaanthracenetriones 6g–6t. Numerical data can be found in Table S5 (Supporting Information).
Molecules 29 00489 g009
Molecules 29 00489 g010
Figure 10. Cytotoxicity of 5,8-dihydro-1,8-diazaanthracenetriones 6u–6aj. Numerical data can be found in Table S5 (Supporting Information).
Figure 10. Cytotoxicity of 5,8-dihydro-1,8-diazaanthracenetriones 6u–6aj. Numerical data can be found in Table S5 (Supporting Information).
Molecules 29 00489 g010
Molecules 29 00489 g011
Figure 11. Cytotoxicity of diazaaquinomycins 1. Numerical data can be found in Table S6 (Supporting Information).
Figure 11. Cytotoxicity of diazaaquinomycins 1. Numerical data can be found in Table S6 (Supporting Information).
Molecules 29 00489 g011
Molecules 29 00489 g012
Figure 12. Activity of compound 6h against MDR cell lines (IC50, μM).
Figure 12. Activity of compound 6h against MDR cell lines (IC50, μM).
Molecules 29 00489 g012
Table 1. Structures of 1-azadienes 9.
Table 1. Structures of 1-azadienes 9.
Molecules 29 00489 i001
Comp.R5R6Comp.R5R6
aHHfPhH
bHMeg4-Me2NC6H4H
cHEthEtMe
dHnBuinPrMe
eMeHjnBuMe
Table 2. Structures of quinones 8.
Table 2. Structures of quinones 8.
Molecules 29 00489 i002
Comp.R1R3R4Comp.R1R3R4
aHHHhp-TolHH
bHHMeiHp-TolH
cMeHMejHHnPr
dHMeMekHMeH
eHBnMelHEtH
fHHEtmHPhH
gHH(CH2)2PhnHCO2EtH
Table 3. Scope and yields of the hetero Diels–Alder reactions.
Table 3. Scope and yields of the hetero Diels–Alder reactions.
Comp. R1R3R4R5R6Method aYield, %
5610
aHHHHHA8108 b
bHHHHEtA7000 b
cHHMeHHA70014 b
dHHMeHMeA (B)48 (88)020  b (0)  c
eHHMeHEtA42033 b
fHHMeHnBuA (C)30 (68)050 (8) f
gHHMeMeHA (C)051 (53)35 b (15)  f
hHHMePhHA03465 b
iHHMe4-Me2NC6H4HA01161 e
jHHMeEtMeA04745 b
kHHMenPrMeA03240
lHMeMeHMeA76011
mHBnMeHMeB6800
nHHEtHMeA7009
oHH(CH2)2PhHMeA (B)49 (82)0 (0)15 (0) c
pp-TolHHHMeD5209
qHp-TolHHMeB9400
rHMeMeMeHA (B)032 (70)42 (6) c
sHHEtMeHA (B)029 (84)59 (0) c
tHHnPrMeHA(B)032 (92)50 (0) c
uHMenPrnPrMeB24460 g
vp-TolHHMeHB0800
wHp-TolHMeHB6400
xHMeHHMeA5000 d
yHEtHHMeA4500 d
zHPhHHMeA5000 d
aaHMeHMeHD4660 d
abHEtHMeHA (B)18 (44)27 (0)7 (0) d
acHPhHMeHD40 020 d
adHCO2EtHHMeA59 00 d 
aeHHMeEtHA (C)028 (70)25 (8) f
afHHMenPrHA (C) 027 (62)65 (8) f
agHHMenBuHA (C)030 (65)50 (8) f
a Method A: Reaction in chloroform at room temperature. Method B: Compound 8 was supported on silica gel, which was eluted with a chloroform solution of compound 9. Method C: Reaction in chloroform in the presence of a chloroformyl polystyrene resin. Method D: reaction according to method B, followed by oxidation with activated manganese dioxide. b Data obtained from reference [33]. c Data obtained from reference [34]. d Data obtained from reference [36]. e Data obtained from reference [46]. f Data obtained from reference [35]. g  Data obtained from reference [44].
Table 4. Scope and yields obtained in the dehydrogenation of compounds 6.
Table 4. Scope and yields obtained in the dehydrogenation of compounds 6.
Comp.R1R3R4R5R6Method aYield, %
5gHHMeMeHA (B)88 (90) b
5hHHMePhHA (B)83 (70) b
5iHHMe4-Me2NC6H4HB80
5jHHMeEtMeA (B)94 (95) b
5kHHMenPrMeA94
5rHMeMeMeHC74 c
5sHHEtMeHB82
5tHHnPrMeHA92
5uHMenPrnPrMeA63 c
5vp-TolHHMeHA94
a Method A: MnO2, CHCl3, rt, 10 min. Method B: Xylene, reflux, 60–120 h. Method C: 10% aq. NaOH, rt. b Data obtained from reference [33]. c Data obtained from reference [44].
Table 5. Structures and yields of compounds 7.
Table 5. Structures and yields of compounds 7.
Comp. R1R4R6R7R8ConditionsYield %
7aHHHHHCHCl3, 95 °C, 2 h (sealed tube)79 a,d
7bMeMeHHHAcOEt, 100 °C, 24 h (sealed tube)81 a
7cHMeMeHHAcOEt, 120 °C, 24 h (sealed tube)64 a,c
7dHMeHHMeAcOEt, 120 °C, 14 h (sealed tube)60 c
7eHMeMeHMeAcOEt, 120 °C, 1 h,
then xylene, 150 °C, 36 h		57 a
7f
(marcanine A)		HMeHHHAcOEt, 120 °C, 24 h (sealed tube)81 b
a Data obtained from reference [49]. b Using 1-methoxy-1,3-butadiene as diene. c Isolated as a 3:1 mixture of 7c and its 7-Me regioisomer, from which a sample for biology was obtained by slow column chromatography on silica gel, eluting with 6:4 dichloromethane-ethyl acetate. d Using 1-trimethylsilyloxy-1,3-butadiene as the diene.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Avendaño, C.; López-Alvarado, P.; Pérez, J.M.; Alonso, M.Á.; Pascual-Alfonso, E.; Ruiz-Serrano, M.; Menéndez, J.C. Structure-Antitumor Activity Relationships of Aza- and Diaza-Anthracene-2,9,10-Triones and Their Partially Saturated Derivatives. Molecules 2024, 29, 489. https://doi.org/10.3390/molecules29020489

AMA Style

Avendaño C, López-Alvarado P, Pérez JM, Alonso MÁ, Pascual-Alfonso E, Ruiz-Serrano M, Menéndez JC. Structure-Antitumor Activity Relationships of Aza- and Diaza-Anthracene-2,9,10-Triones and Their Partially Saturated Derivatives. Molecules. 2024; 29(2):489. https://doi.org/10.3390/molecules29020489

Chicago/Turabian Style

Avendaño, Carmen, Pilar López-Alvarado, José María Pérez, Miguel Ángel Alonso, Eva Pascual-Alfonso, Miriam Ruiz-Serrano, and J. Carlos Menéndez. 2024. "Structure-Antitumor Activity Relationships of Aza- and Diaza-Anthracene-2,9,10-Triones and Their Partially Saturated Derivatives" Molecules 29, no. 2: 489. https://doi.org/10.3390/molecules29020489

Article Metrics

Back to TopTop